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Abstract 
Glaucoma is a chronic ocular neuropathy and a leading cause of blindness 
worldwide. Primary open-angle glaucoma (POAG) is the most common subtype with an 
estimated 2 million affected individuals in the Unites States. POAG is a heritable 
complex trait. Understanding the genetics of POAG may increase our ability to predict 
disease onset and help elucidate the underlying biological mechanisms responsible for 
the development of the disease. With this overall goal, three different approaches are 
presented here. 
First, the genetics of an important POAG-associated trait, central corneal 
thickness (CCT), was investigated using genome-wide single nucleotide polymorphism 
(SNP) data available from the NEIGHBOR and GLAUGEN consortia to identify novel 
POAG candidate genes. Twenty previously published CCT-associated SNPs were tested 
for association with both CCT (N = 1,117) and POAG (N = 6,470). While several of these 
variants were significantly associated with CCT in our dataset (top SNP = rs12447690, 
near ZNF469 (beta = -5.08 µm/allele; p = 0.001), none were associated with POAG. A 
CCT genome-wide association study was conducted. Using a p-value threshold of   
1X10-4, 50 candidate SNPs were tested for association with POAG. One SNP, rs7481514, 
within the NTM gene was significantly associated with POAG in a low tension subset of 
cases (odds ratio (OR) = 1.28; p = 0.001). Additionally, SNPs in the CNTNAP4 gene 
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showed suggestive evidence of association with POAG (top SNP = rs1428758; OR = 0.84; 
p = 0.018). A gene expression analysis showed evidence of NTM and CNTNAP4 gene 
expression in relevant ocular tissues. This study suggests previously reported CCT loci 
do not increase POAG susceptibility. However, by using a two-step gene mapping 
approach, the cell adhesion molecules, NTM and CNTNAP4, were identified as potential 
POAG candidate genes in a subset of cases. 
The second study aimed to identify functional alleles within a POAG candidate 
gene. Previous association studies identified a significant association between POAG 
and the SIX6 locus (top SNP = rs10483727, OR = 1.32, p = 3.87X10-11). SIX6 plays a role in 
ocular development and has been associated with the morphology of the optic nerve. 
Sequencing of the SIX6 coding and regulatory regions in 262 POAG cases and 256 
controls identified six nonsynonymous coding variants. Of these six, five were rare 
(minor allele frequency (MAF) < 0.002) and one, Asn141His (rs33912345), was a common 
variant that showed a significant association with POAG (OR = 1.27, p = 4.2X10-10) in the 
NEIGHBOR/GLAUGEN dataset. These variants were tested in an in vivo zebrafish 
complementation assay to evaluate ocular metrics. Five of the six alleles had a functional 
effect on the protein. These five variants, found primarily in POAG cases, were 
hypomorphic or null, while a sixth variant, found only in controls, was benign. One 
variant in the SIX6 enhancer increased expression of the SIX6 gene and disrupted its 
regulation. Using optical coherence tomography, the retinal thickness of POAG with and 
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without the common SIX6 risk allele, Asn141His (rs33912345), was measured. Patients 
who are homozygous for the SIX6 risk allele (His141) have a statistically thinner retinal 
nerve fiber layer than patients homozygous for the SIX6 non-risk allele (Asn141). These 
results in combination with previous SIX6 work, leads us to hypothesize that SIX6 risk 
variants disrupt the development of the neural retina and result in a reduced number of 
retinal ganglion cells generated during development, thereby increasing the risk of 
glaucoma-associated vision loss later in life. 
Next, the transcriptional landscape of three POAG-related tissues; the trabecular 
meshwork, the cornea, and the ciliary body; were evaluated using an RNA sequencing 
(RNA-seq) approach. Tissues were selected from two fetal and four adult human donor 
samples with no known history of ocular disease. Deep RNA-seq was performed, and 
the total number of paired reads per sample ranged from 32,137,380 to 59,784,117. A 
descriptive analysis was conducted and included the identification of the top most 
expressed genes in each tissue and the distribution of gene expression values. 
Additionally, gene expression of selected POAG candidate genes (CDKN2B, CDKN2A, 
CDKN2B-AS, SIX6, SRBD1, ATOH, CAV1, CAV2, ELOVL5, and TMCO1) was evaluated. 
Most of these genes showed high expression values in the trabecular meshwork and 
cornea. ATOH was only found to be expressed in the fetal TM and, interestingly, SIX6 
was shown to be highly expressed in the adult and fetal ciliary body. CDKN2B-AS was 
not found to be expressed in any of the tissues evaluated. Finally, the RNA-seq data was 
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used to identify potential novel isoforms of these candidate genes. Using a stringent 
threshold, five novel isoforms were identified in CDKN2B, SRBD1, and SIX6. The data 
generated as part of this study can be used to develop novel hypotheses, guide future 
work, and is broadly applicable for ocular research because the tissues included in this 
analysis are essential for normal vision and play important roles in ocular diseases.  
In this dissertation, three different approaches (assessment of a quantitative risk 
factor, candidate gene functional analysis, and the assessment of the transcriptional 
landscape of relevant ocular tissues) were used to study the common blinding disorder, 
primary open-angle glaucoma. Continued research in this field is essential. There is a 
need for increased functional follow-up of genetic association studies in order to identify 
true causal susceptibility genes and improve our understanding of POAG biology. 
Additionally, researchers should focus on building and implementing accurate 
prediction models to increase POAG diagnosis rates and preemptive treatment. 
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1. Introduction 
1.1 Primary open-angle glaucoma (POAG) epidemiology 
Glaucoma is a chronic, bilateral optic neuropathy characterized by the 
progressive loss of retinal ganglion cells and visual field. It is the second leading cause 
of blindness with an estimated 60 million affected individuals worldwide (Resnikoff, 
Pascolini et al. 2004; Quigley and Broman 2006). Glaucoma is divided into subgroups 
based on clinical presentation. The most common subtype, primary open-angle 
glaucoma (POAG), is classified by the absence of a known secondary cause and an open 
iridocorneal angle (Allingham, Liu et al. 2009; Kwon, Fingert et al. 2009).  
There are over 2 million POAG patients in the United States alone, and it is the 
leading cause of blindness in African Americans (Tielsch, Sommer et al. 1991; Racette, 
Wilson et al. 2003; Quigley and Broman 2006; Kwon, Fingert et al. 2009). The mean 
prevalence of POAG in individuals over the age of 40 from eight geographic regions are 
estimated to be the following: Africa 4.16%; Japan 3.31%; Latin American 3.16%; Europe 
and the U.S 1.97%; India 1.75%; China 1.40%; Middle East 1.31%; and South East Asia 
1.18% (Quigley and Broman 2006). There are 4.47 million individuals with bilateral 
blindness due to POAG, and this number is estimated to grow as high as 5.6 million by 
2020 (Quigley and Broman 2006). POAG onset and progression typically goes unnoticed 
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until visual impairment and irreversible optic nerve damage has occurred. The 
diagnosis rates are only 34% and 8% in developed and developing countries 
respectively, highlighting the importance of research aimed at increasing our 
understanding of POAG etiology (Quigley and Broman 2006).  
1.2 POAG biology and treatment 
Tissues from both the anterior and posterior portions of the eye are involved in 
the development of POAG, although ultimately POAG is defined by visual field loss due 
to retinal ganglion cells (RGC) death. The axons of these cells form the optic nerve, 
which is responsible for transmitting visual information to the brain’s visual cortex. 
Optic nerve deformation caused by elevated ocular pressure is believed to be a primary 
contributor to POAG. Intraocular pressure is regulated by the intricate balance of 
aqueous humor inflow and outflow. Aqueous humor, generated from the ciliary body, is 
a clear, watery fluid used for circulation in the eye. It flows from the ciliary body, 
through the anterior chamber, and out through the trabecular meshwork, a porous and 
dynamic tissue. Elevated ocular pressure is the result of aqueous humor outflow 
occlusion (Kwon, Fingert et al. 2009). Blockage of this circulation pattern is observed in 
POAG patients and causes ocular hypertension, resulting in RGC loss via mechanical 
stress to the retina and optic nerve (Ray and Mookherjee 2009; Janssen, Gorgels et al. 
2013). Other purposed mechanisms include retina and optic nerve head blood perfusion 
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deficiency, oxidative stress, glutamate excitotoxicity, autoimmunity and inflammation, 
among others (Kuehn, Fingert et al. 2005; Ray and Mookherjee 2009; Janssen, Gorgels et 
al. 2013). In actuality, it is likely that POAG is caused by a combination of these factors 
along with environmental and genetic effects. Although the field of POAG research is 
dense, the underlying biological mechanisms remain poorly understood due to the 
complex and heterogeneous nature of the disease. More work is needed to fully 
elucidate the true processes responsible for POAG development.  
POAG treatments have traditionally focused on the reduction of intraocular 
pressure, considered the only treatable risk factor. Patients may either be prescribed 
pressure reducing eye drops, undergo ocular surgery, or both. Topical medications are 
often associated with systemic side effects and suffer from patient compliance issues 
(Kulkarni et al.) Surgical techniques aimed at improving aqueous humor drainage are 
often used as a second line of therapy. The most aggressive surgical technique, a 
trabeculectomy, is effective for the short term reduction in intraocular pressure (Boland, 
Ervin et al. 2013). However, there is a risk of complications associated with ocular 
surgery, patients often require repeat treatment, and the long-term effectiveness is 
unclear (Wilensky and Chen 1996; Kulkarni, Damji et al. 2008; Allingham and Shields 
2011). Treatment methods reduce intraocular pressure by either decreasing aqueous 
humor production or by enabling increased outflow capabilities. It should be noted that 
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not all POAG cases present with elevated ocular pressure, and currently it is unclear if 
normal tension glaucoma (POAG with an absence of ocular hypertension) shares the 
same underlying biological mechanism as high tension glaucoma. However, studies 
show that ocular pressure reducing therapies mitigate disease progression even in 
normal tension glaucoma cases (Collaborative Normal-Tension Glaucoma Study Group 
1998; Heijl, Leske et al. 2002; Miglior, Pfeiffer et al. 2007). 
1.3 POAG risk factors 
Elevated intraocular pressure is the most well established risk factor for the 
development and progression of POAG. Other commonly accepted risk factors include 
age, family history, race, thinner corneal thickness, and optic nerve cupping parameters 
(measurements commonly used to diagnosis and track POAG progression) (Gordon, 
Beiser et al. 2002; Leske, Heijl et al. 2007; Miglior, Pfeiffer et al. 2007; Kwon, Fingert et al. 
2009; Janssen, Gorgels et al. 2013). Sex, diabetes mellitus, decreased diastolic profusion 
pressure, cardio vascular disease, and myopia have all been considered as potential risk 
factors, but the results have been inconsistent (Miglior, Pfeiffer et al. 2007; Kwon, Fingert 
et al. 2009; Gibson, Griffiths et al. 2012). Additionally, there is growing evidence that 
intracranial pressure may play a role in POAG pathogenicity. It is hypothesized that 
intracranial pressure balances the opposing intraocular pressure to sustain the integrity 
of the optic nerve head. Thus, a reduced intracranial pressure results in an increased 
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sensitivity to elevated or fluctuating intraocular pressure (Fleischman and Allingham 
2013; Janssen, Gorgels et al. 2013).This emphasizes the importance of intraocular 
pressure regulation in POAG. Individuals with intraocular pressure above the normal 
range (10 to 21 mm Hg) have a 3 -39 times increased risk of developing POAG, 
depending on the level of ocular hypertension (Sommer, Tielsch et al. 1991; Kwon, 
Fingert et al. 2009). It is estimated that 30-40% of POAG cases have an intraocular 
pressure in the normal range, and this is estimated to be even higher in Hispanic and 
Japanese populations (Dielemans, Vingerling et al. 1994; Iwase, Suzuki et al. 2004; 
Varma, Ying-Lai et al. 2004; Mudumbai 2013). A decreased intracranial pressure may 
play a larger role in this subset of POAG. 
POAG is generally considered a late age disease, occurring after the age of 40. 
Alternative forms include primary congenital glaucoma (birth to 3 years age of onset) 
and juvenile open-angle glaucoma (3 to 20 years age of onset), although these are 
generally considered to be separate diseases (Kwon, Fingert et al. 2009). Increased age is 
known to increase the risk of developing POAG by 20-40% for each decade after the age 
of 40 (Coleman and Miglior 2008). 
Many quantitative ocular measurements are considered POAG risk factors 
including corneal thickness and optic nerve head measurements, particularly vertical 
cup-disc ratio. Central corneal thickness (CCT) is consistently shown to be reduced in 
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POAG cases compared to controls; there is a 1.7 times increased risk per 40 µm decrease 
in CCT (Gordon, Beiser et al. 2002; Racette, Wilson et al. 2003; Leske, Heijl et al. 2007; 
Miglior, Pfeiffer et al. 2007; Coleman and Miglior 2008). While the Ocular Hypertension 
Treatment study showed CCT is independently associated with POAG, others question 
its true relationship with POAG due to confounding factors. CCT is known to influence 
intraocular pressure measurements, and the effect of prescribed topical medications for 
POAG treatment on CCT remains unclear (Janssen, Gorgels et al. 2013). Nevertheless, 
the strong association observed between CCT and POAG has warranted many research 
studies, discussed in greater detail in Chapter 2. Similarly, vertical cup-disc ratio 
(VCDR) has been associated with POAG and is considered a predictive risk factor due to 
the fact that VCDR is used to measure POAG disease progression (Gordon, Beiser et al. 
2002; Coleman and Miglior 2008). A genetic locus at Chromosome 14q22-23 is associated 
with both VCDR and POAG (Macgregor, Hewitt et al. 2010; Ramdas, van Koolwijk et al. 
2010; Fan, Wang et al. 2011; Osman, Low et al. 2012; Wiggs, Yaspan et al. 2012). A 
functional analysis of this locus is presented in Chapter 3. 
African ancestry has been consistently shown to increase the risk of developing 
POAG (Tielsch, Sommer et al. 1991; Gordon, Beiser et al. 2002; Racette, Wilson et al. 
2003; Quigley and Broman 2006; Rudnicka, Mt-Isa et al. 2006). The Ocular Hypertension 
Treatment study found that African Americans have a 59% increased risk of developing 
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POAG (Gordon, Beiser et al. 2002). However, there are racial differences in many ocular 
parameters and, on average, individuals of African ancestry have thinner corneas, larger 
optic cups, larger cup-disc ratios, and thinner retinal nerve fiber layers—all parameters 
associated with POAG risk and progression (Racette, Wilson et al. 2003). The Ocular 
Hypertension Treatment study showed that race is no longer significantly associated 
with POAG in multivariate models adjusted for corneal thickness or cup-disc ratio, 
suggesting African ancestry may increase risk of POAG via inherent, quantitative ocular 
parameters (Gordon et al). 
1.4 POAG genetics 
POAG is a heritable, complex disease; both sporadic and familial forms exist. 
Previous studies have reported that approximately 50% of POAG cases have a family 
history of the disease, and the risk of developing POAG is 3-9 times greater in 
individuals with an affected first degree relative ((Tielsch, Katz et al. 1994; Wolfs, Klaver 
et al. 1998; Weih, Nanjan et al. 2001; Wu, Hewitt et al. 2006). Congenital and juvenile 
forms of POAG are often inherited in either an autosomal dominant or autosomal 
recessive manner, while adult-onset POAG is considered a complex trait with 
multigenic inheritance (Liu and Allingham 2011; Janssen, Gorgels et al. 2013). Generally, 
familial forms of POAG are more severe and have an earlier average age of onset (Wu, 
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Hewitt et al. 2006). Taken together, these data suggest POAG likely has a genetic 
component.  
The search for glaucoma genes began with linkage studies, an approach that 
relies on the collection of nuclear families or extended families with multiple affected 
individuals. These family-based studies identified 20 loci linked to POAG, and within 
these loci several likely disease causing genes have been identified including MYOC, 
OPTN, WDR36, and CY1B1 (for primary congenital glaucoma). Detailed reviews of these 
loci are available (Allingham, Liu et al. 2009; Liu and Allingham 2011; Gemenetzi, Yang 
et al. 2012; Janssen, Gorgels et al. 2013). For the most part, mutations in these genes are 
limited to early-onset POAG cases and only explain 3-5% of adult-onset cases. The 
genetics of the majority of POAG cases remain poorly understood and are likely due to 
multigenic and environmental effects, consistent with a complex etiology (Allingham, 
Liu et al. 2009; Liu and Allingham 2011; Janssen, Gorgels et al. 2013).  
As an alternative to linkage analysis, genome-wide association studies (GWAS) 
have also been used for POAG disease gene identification. This approach, like linkage 
mapping, is unbiased and does not rely on an a priori hypothesis, but unlike linkage 
mapping, is applicable for case-control datasets. Many successful POAG GWAS have 
been conducted, and these studies have been performed in POAG cases with normal 
and high ocular pressure from various populations (Nakano, Ikeda et al. 2009; Meguro, 
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Inoko et al. 2010; Thorleifsson, Walters et al. 2010; Burdon, Macgregor et al. 2011; 
Burdon 2012; Gibson, Griffiths et al. 2012; Osman, Low et al. 2012; Wiggs, Yaspan et al. 
2012; Janssen, Gorgels et al. 2013). The most commonly identified and replicated loci 
include CAV1/CAV2 (Chr. 7q31.1), CDKN2B (Chr. 9p21), SIX1/SIX6 (Chr. 14p22-23), and 
TMCO1 (Chr. 1q24) (Burdon 2012; Janssen, Gorgels et al. 2013). In addition, other 
commonly used disease gene identification approaches have been used in POAG studies 
including a candidate gene approach (where genes are selected for analysis based on 
predefined, biological driven hypotheses) and endophenotype analysis (where the 
genetics of potential endophenotypes are used to identify disease genes). For an 
extensive review of genes associated with POAG and related endophenotypes, please 
see the recently published review by Janseen et al. (Janssen, Gorgels et al. 2013). Despite 
the success in the field of POAG genetics, the functional role of genes identified using 
these methods remains unclear. This fact highlights the current need for focused 
functional follow-up of POAG genetic association studies.  
Complex diseases such as POAG exhibit substantial etiologic and genetic 
heterogeneity. Therefore, identifying POAG susceptibility alleles requires the use of a 
variety of approaches and techniques including family-based linkage analysis, 
case/control association analysis, and bioinformatics approaches. Three methods are 
presented here: (Chapter 2) the genetic assessment of a quantitative POAG risk factor; 
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(Chapter 3) the functional analysis of a POAG candidate gene; and (Chapter 4) the 
transcriptome analysis of ocular tissues- all with the shared goal of increasing our 
understanding of the biology and genetic mechanisms responsible for the development 
and progression of POAG.  
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2. Central corneal thickness (CCT) analysis: a potential 
POAG endophenotype
1
 
2.1 Introduction 
The cornea is responsible for the majority of the eye’s refractive power, and its 
structure is therefore an important part of normal vision. The cornea is a highly 
collagenous, transparent tissue that is a continuation of the sclera, which posteriorly 
supports the optic nerve. A reduction in central corneal thickness (CCT) has been 
observed in a number of systemic and ocular diseases including Ehlers-Danlos 
syndrome, osteogenesis imperfecta, keratoconus, and brittle cornea syndrome (Dimasi, 
Chen et al. 2010; Lu, Dimasi et al. 2010; Vitart, Bencic et al. 2010; Vithana, Aung et al. 
2011). Reduced CCT has also been associated with an increased risk of primary open-
angle glaucoma (POAG), the second leading cause of blindness worldwide (Gordon, 
Beiser et al. 2002; Dimasi, Burdon et al. 2010). In POAG, CCT has been shown to be a risk 
factor independent of other known risk factors including advanced age and elevated 
intraocular pressure, and has been linked with increased disease severity and rapid 
disease progression (Gordon, Beiser et al. 2002; Leske, Heijl et al. 2007; Miglior, Pfeiffer 
et al. 2007; Dimasi, Burdon et al. 2010). Elucidating the genetics of CCT may lead to 
                                                   
1 This chapter is a modification of an earlier publication which appeared as Ulmer, M., J. Li, et al. (2012). 
"Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the 
NEIGHBOR and GLAUGEN consortia." Invest Ophthalmol Vis Sci 53(8): 4468-4474. The copyright of the 
original article is held by the Association for Research in Vision and Ophthalmology. 
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identification of novel POAG risk genes and could improve our understanding of the 
molecular mechanism driving this association.  
CCT has been shown to be a normally distributed quantitative trait with 
heritability estimates as high as 95% (Dimasi, Burdon et al. 2010). Several studies have 
been successful in identifying CCT loci through candidate gene and genome-wide 
approaches. An Australian and UK cohort study first identified the ZNF469 gene, an 
uncharacterized zinc-finger protein, and FOXO1, a member of the forkhead family of 
transcription factors, in a genome-wide analysis of CCT (Lu, Dimasi et al. 2010). The 
ZNF469 locus has been replicated in follow-up studies in Croatian, Scottish, and Asian 
populations (Vitart, Bencic et al. 2010; Cornes, Khor et al. 2011; Vithana, Aung et al. 
2011). Consistent with the belief that CCT is a complex quantitative trait with multigenic 
inheritance, these studies have also identified numerous other loci in genomic regions 
containing collagen V alpha-1 (COL5A1), collagen VIII alpha-2 (COL8A2), A-kinase 
anchor protein 13 (AKAP13), inhibitor of Bruton’s tyrosine kinase (IBTK), leucine-rich 
repeat kinase 1 (LRRK1), and multiple intergenic regions (Vitart, Bencic et al. 2010; 
Cornes, Khor et al. 2011; Vithana, Aung et al. 2011). 
Due to the strong association observed between CCT and POAG, CCT has been 
considered as a possible POAG endophenotype (Gordon, Beiser et al. 2002; Leske, Heijl 
et al. 2007; Gemenetzi, Yang et al. 2012). Identification of complex disease genes through 
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a quantitative endophenotype has many advantages and has been successful in POAG 
with other quantitative risk factors (Charlesworth, Kramer et al. 2010; Desronvil, Logan-
Wyatt et al. 2010; Ramdas, van Koolwijk et al. 2010; Ramdas, van Koolwijk et al. 2011). 
Disease genes can be identified by first studying the genetics of the endophenotype 
based on the assumption that candidate genes will be associated with both traits. Using 
this methodology, we investigate the effects of previously reported CCT-associated 
genetic variants on POAG risk. Although these genome-wide studies have successfully 
identified genetic variants associated with CCT, they have been performed in primarily 
non-glaucomatous population cohorts. It is possible that POAG cases have additional 
variants associated with CCT compared to normal populations and that these variants 
may explain the underlying molecular mechanism driving the association between 
reduced CCT and POAG risk. Therefore, we then performed a genome-wide CCT 
analysis in a primarily POAG case population to identify a novel list of candidate 
variants and tested the effects of these single nucleotide polymorphisms (SNPs) using a 
larger POAG case-control population.  
2.2 Materials and methods 
2.2.1 Study population  
Data were available from the NEI Glaucoma Human Genetics Collaboration 
(NEIGHBOR) and the Glaucoma Genes and Environment (GLAUGEN) consortia 
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(Wiggs, Hauser et al. 2012; Wiggs, Yaspan et al. 2012). These studies were approved by 
the Institutional Review Boards of the Massachusetts Eye and Ear Infirmary, the 
Harvard University School of Public Health, the Brigham and Woman’s Hospital, and 
Duke University. All human subject research adhered to the tenets of the Declaration of 
Helsinki. POAG cases for both studies were defined as individuals with glaucomatous 
optic neuropathy with reproducible visual field tests or a cup-disc ratio of > 0.7 in at 
least one eye. POAG cases were grouped into two subsets based on intraocular pressure 
(IOP) for stratified analyses. A low tension subset was defined by an IOP of < 21 mm Hg 
at the time of sample collection with no history of IOP greater than 21 mm Hg (either by 
self-report or by chart review). A total of 705 POAG cases met the low tension definition 
while 1,629 POAG cases with a history of any IOP > 21 mm Hg were included in the 
high tension subset. POAG controls had normal IOP (< 21 mm Hg), no evidence of 
visual field loss, and a normal cup-disc ratio (< 0.7). 
2.2.2 CCT association analysis 
CCT measurements were available for 851 individuals from the NEIGHBOR 
study and 325 individuals from the GLAUGEN study. For the CCT analysis, we used the 
mean CCT from both eyes as our analysis outcome variable because we observed a 
strong correlation between right eye CCT and left eye CCT (R2 = 0.92 in GLAUGEN; R2 = 
0.83 in NEIGHBOR). We removed 10 outliers in GLAUGEN and 16 outliers in 
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NEIGHBOR, which were defined by large left-right eye CCT differences (beyond 2.5 
standard deviation of the overall distribution of left-right differences). A lack of left-
right eye correlation could be due to true right and left eye CCT differences, 
measurement artifacts, or unknown corneal defects. Additionally, we removed 
individuals with known corneal diseases, non-Caucasian ancestry, and one distribution 
outlier with an extremely small average CCT value (< 374 µm). Population substructure 
was assessed by principal components analysis performed using Eigenstrat (Price, 
Patterson et al. 2006) and outliers were removed from the analysis (Appendix A). After 
data cleaning, our CCT dataset consisted of 1,117 individuals including 668 POAG cases 
and 144 POAG controls from the NEIGHBOR study and 305 POAG cases from the 
GLAUGEN study (Table 1). 
We assessed CCT distribution differences among a variety of clinical variables 
including POAG case status, CCT measurement device, DNA source (blood versus 
cheek), DNA extraction method (Qiagen, DNAzol, GENTRA), history of laser 
trabeculoplasty, and incisional glaucoma filtration surgery using the Student’s t-test 
calculated in SAS (SAS Institute Inc. 2002-2008). Only POAG case status and CCT 
measurement device were associated with CCT and were included as covariates in the 
final model. Genotyping was performed using the Illumina Human660W-Quad v1 
BeadChip array and was previously filtered using quality control metrics, as described 
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(Wiggs, Yaspan et al. 2012). The final dataset contained 480,304 cleaned SNPs shared 
between the two studies. SNPs were tested for association with average CCT using 
linear regression performed in PLINK (Purcell, Neale et al. 2007), adjusted for age, sex, 
instrument used to measure CCT, and POAG case/control status. A Manhattan plot and 
a quantile-quantile plot (Appendix B) of the resulting p-values were generated in R 
(http://www.R-project.org) using code provided by Getting Genetics Done  
(http://gettinggeneticsdone.com/). Linkage disequilibrium was calculated and visualized 
using the Haploview program (Barrett 2009). 
2.2.3 POAG association analysis 
Candidate SNPs were tested for association with POAG risk in the full 
NEIGHBOR and GLAUGEN datasets. After quality control filtering including removal 
of sex mismatches, duplicate samples, and population outliers, the final dataset 
contained 2125 POAG cases and 2251 POAG controls from the NEIGHBOR study and 
964 POAG cases and 1130 POAG controls from the GLAUGEN study2. In the 
NEIGHBOR study, logistic regression models included age, sex, collection site, and 4 
principal components as covariates. In the GLAUGEN study, the method of DNA 
extraction, the specimen type (blood vs. cheek), and site were found to be independently 
                                                   
2 Sample collection, genotyping, and initial quality control filtering (removal of failed SNPs) was conducted 
by members of the NEIGHBOR and GLAUGEN consortia, as described in Wiggs, J. L., B. L. Yaspan, et al. 
(2012). "Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve 
degeneration in glaucoma." PLoS Genet 8(4): e1002654. 
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associated with both DNA quality and POAG case/control status and were included in 
logistic regression models along with age, sex, and 6 principal components. A formal 
meta-analysis of the two studies was conducted in PLINK (Purcell, Neale et al. 2007). 
POAG risk was assessed in the overall dataset, the low tension subset, and the high 
tension subset. 
2.2.4 Gene expression analysis 
To determine the presence of candidate gene expression in relevant tissues, 
cDNA was prepared from human adult and fetal brain and ocular tissue samples3. Adult 
and fetal brain cDNA libraries were generated from the Human Total RNA Master Panel 
II from Clontech Laboratories, Inc. (California, USA). A fetal ocular sample from a 24 
week gestation period was obtained from Advanced Biosciences Resources (California, 
USA) and was preserved in RNAlater (Qiagen, Limburg, Netherlands) within minutes of 
collection. An adult eye was provided by the North Carolina Eye Bank. This sample was 
collected 5 hours and 10 minutes post-mortem and was preserved in RNAlater. We 
dissected the cornea, optic nerve, and sclera wall from each eye. The cornea was isolated 
using a 5 mm biopsy punch at the center of the cornea, optic nerve samples were 
collected using dissection scissors, and the scleral tissue was isolated using a 7 mm 
                                                   
3 Ocular tissue dissections and cDNA synthesis was performed by Dr. Felicia Hawthorne at the Duke Center 
for Human Genetics. The subsequent gene expression assay and analysis was performed by Megan Ulmer 
Carnes. 
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biopsy punch centered behind the fovea. To reduce retinal contamination of the scleral 
sample, a second 5 mm biopsy was taken from the center of the 7 mm punch after 
complete removal of the retina. Messenger RNA (mRNA) was extracted from each tissue 
sample independently using the mirVana total RNA extraction kit (Ambion, Texas, 
USA). Quality control for each sample included measuring RNA concentration and RNA 
subunit ratios at 260/280 nm using the NanoDrop technology (Invitrogen, California, 
USA). We generated cDNA from each mRNA library using the SuperScript III First-
Strand Synthesis kit (Invitrogen). 
 We then used the brain, cornea, optic nerve, and sclera cDNA libraries to 
perform polymerase chain reaction (PCR) assays to determine the presence or absence of 
contactin-associated protein-like 4 (CNTNAP4) and neurotrmin (NTM) gene expression. 
The PCR assays contained 2 uL cDNA, 1 X PCR buffer, 200 µmol/ each dNTP, 1.5 mM 
MgCl2, 200 ng of the forward primer, 200 ng of the reverse primer, and 3 U of Platinum 
Taq DNA polymerase (Invitrogen). Primers were designed using Primer3 (Rozen and 
Skaletsky 2000) and spanned intron-exon boundaries. The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was used as a control to check for cDNA quality. 
CNTNAP4, NTM, and GAPDH were amplified (primer sequences are available in 
Appendix C) using a touchdown PCR protocol with the following conditions: 94°C for 3 
minutes; 2 cycles of 94°C for 5 seconds, 61°C for 30 seconds, and 72°C for 30 seconds 
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repeated using an incremental 2°C decrease in annealing temperature until 51°C was 
reached; followed by 30 cycles with a 51°C annealing temperature; and a final extension 
at 72°C for 3 minutes. The PCRs were purified using Invitrogen’s PureLink Quick Gel 
Extraction Kit, and the products were verified by sequencing at Eton Bioscience, Inc. 
(North Carolina, USA). The results were visualized on an ethidium bromide stained, 
1.5% agarose gel. 
2.3 Results 
2.3.1 Dataset characteristics 
We compared the CCT between POAG cases and controls. The two groups were 
significantly different (p = 0.0002), with a mean (standard deviation) of 557.7 (33.80) µm 
in POAG controls and 545.9 (35.85) µm in POAG cases (Table 1). We also observed a 
significant difference (p = 0.008) in the distribution of CCT in the low tension POAG 
cases compared to high tension cases (Table 1). The high tension subset had a mean CCT 
of 548.4 (35.87) µm, while the low tension POAG cases had a mean CCT of 541.8 (36.10) 
µm. We found that the instrument used to measure CCT (DGH Technology, Inc. 
ultrasound table unit versus a portable handheld unit) had a significant effect (p < 
0.0001, Table 1). Within our CCT dataset, history of laser trabeculoplasty and glaucoma 
filtration surgery was available for 422 POAG cases. We did not see a difference in CCT 
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when we compared individuals with or without a history of laser trabeculoplasty (p = 
0.86) or glaucoma filtration surgery (p = 0.62).  
 
Table 1: Population characteristics of the CCT dataset 
CCT Dataset N Mean (SD) 
Total 1117  
Age (years) 1117 61.6 (12.58) 
Sex (% male) 1117 48.9% 
CCT (µm) 1117  
        *POAG Control 144 557.7 (33.80) 
        *POAG Case 973 545.9 (35.85) 
           *Standard pachymeter 1010 545.6 (35.33) 
        *Portable  pachymeter 107 565.0 (35.60) 
           *POAG cases, low tension 307 541.8 (36.10) 
        *POAG cases, high tension 625 548.4 (35.87) 
 
 
2.3.2 Population-based CCT associated variants and their effect on 
POAG risk 
We looked for evidence of association for 20 previously published CCT SNPs 
(Table 2) in the NEIGHBOR/GLAUGEN CCT dataset (N = 1,117). Using a Bonferroni 
multiple testing correction significance threshold of 0 .0025 (0.05/20), one SNP, 
rs12447690 upstream of ZNF469 (β = -5.08 µm/minor allele, p = 0.001) showed significant 
evidence of association with CCT. Three additional SNPs showed suggestive evidence of 
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association: rs7044529 in COL5A1 (β = -6.58 µm/allele, p = 0.003), rs1536478 in the 
RXRA/COL5A1 intergenic region (β = 4.47 µm/allele, p = 0.004), and rs1538138 near IBTK 
(β = -4.98 µm/allele, p = 0.004) (Table 2). The direction and the effect size estimated for 
these four variants are consistent with previous reports (Lu, Dimasi et al. 2010; Vitart, 
Bencic et al. 2010; Cornes, Khor et al. 2011; Vithana, Aung et al. 2011). We assessed the 
association of these 20 SNPs with POAG case/control status in the larger 
NEIGHBOR/GLAUGEN meta-analysis in the overall dataset (N = 6,470), low tension (N 
= 4,086), and high tension (N = 4,966) subsets. Using the same significance threshold as 
above (0.0025), none of these SNPs showed any evidence of association with POAG 
(Table 2).    
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Table 2: Association results from the CCT and POAG analyses for 20 previously 
reported CCT-associated variants 
The association results of 20 SNPs previously found to be associated with CCT are 
shown. The beta (µm) and odds ratio (OR) represent the effect size for each copy of the 
minor allele. 
   CCT Analysis  
(N = 1,117) 
POAG Analysis  
(N = 6,470) 
SNP Chr. Locus Beta P OR P 
rs3767703 1 Col8A2 -2.37 0.37 0.95 0.51 
rs7550047 1 Col8A2 -2.78 0.27 0.98 0.78 
rs96067 1 Col8A2 -0.83 0.66 0.94 0.20 
rs11694554 2 Col4A3 3.82 0.10 1.14 0.25 
rs1538138 6 IBTK -4.98 0.004 0.96 0.42 
rs1324183 9 9p23 -3.66 0.04 1.09 0.09 
rs1409832 9 RXRA/COL5A1 -3.31 0.06 1.09 0.07 
rs1536478 9 RXRA/COL5A1 4.47 0.004 0.99 0.87 
rs1536482 9 RXRA/COL5A1 -1.69 0.29 1.04 0.38 
rs7044529 9 COL5A1 -6.58 0.003 0.99 0.86 
rs1034200 13 AVGR8 2.9 0.08 0.94 0.31 
rs2721051 13 FOXO1 -4.69 0.04 1.02 0.75 
rs2755237 13 FOXO1 -1.66 0.4 1.06 0.28 
rs1828481 15 AKAP13 0.11 0.94 0.96 0.29 
rs4965359 15 LRRK1 -2.82 0.07 0.99 0.81 
rs6496932 15 PDE8A/AKAP13 -2.35 0.22 1.05 0.30 
rs7172789 15 AKAP13 0.23 0.88 0.95 0.25 
rs930847 15 LRRK1 2.15 0.23 0.97 0.47 
rs12447690 16 ZNF469 -5.08 0.001 1.04 0.33 
rs9938149 16 ZNF469 -3.84 0.01 1.05 0.24 
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2.3.3 CCT genome-wide association study 
Next, we performed a CCT GWAS to identify novel candidate SNPs using the 
CCT dataset. No SNP met the genome-wide significance threshold of 1 X 10-7 (Figure 1), 
either in the overall dataset or when the analysis was confined to only POAG cases.  
 
Figure 1: Manhattan plot showing the results of the CCT GWAS from the 
NEIGHBOR/GLAUGEN CCT dataset 
The red line (upper) indicates the genome-wide significance threshold (p-value 
of 1 X 10-7), the blue line (middle) indicates the suggestive significance threshold (p-
value of 1 X 10-5), and the black line (lower) indicates the threshold level selected for a 
follow-up POAG association analysis (p-value of 1 X 10-4). 
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The top five most significant SNPs (Table 3, Figure 1) were located on 
chromosome (Chr.) 2 at PRKCE (rs10205024, β = -7.49 µm/allele, p = 1.68 X 10-6); on Chr. 
16 at the CNTNAP4 gene (rs9939043, β = 7.15 µm/allele, p = 2.70 X 10-6); on Chr. 20 at the 
HAO1 gene (rs2423322, β = -9.03 µm/allele, p = 4.48 X 10-6); in an intergenic region on 
Chr. 7 at the EMID2/MYL10 locus (rs17135662, β = 8.31 µm/allele, p = 8.69 X 10-6); and on 
Chr. 11 at the NTM gene (rs7108536, β = -6.78 µm/allele, p = 1.00 X 10-5).  
 
Table 3: Top ten most significant SNPs from the CCT GWAS 
The top ten SNPs from the CCT GWAS are shown. The beta (µm) represents the effect 
size for each copy of the minor allele, given in the allele column. 
Chr. SNP Locus Allele Beta p 
2 rs10205024 PRKCE A -7.49 1.68 X 10-06 
16 rs9939043 CNTNAP4 A 7.15 2.70 X 10-06 
20 rs2423322 HAO1 A -9.03 4.48 X 10-06 
7 rs17135662 EMID2/MYL10 A 8.31 8.69 X 10-06 
11 rs7108536 NTM G -6.78 1.00 X 10-05 
11 rs7481514 NTM A -6.89 1.03 X 10-05 
16 rs2866710 CNTNAP4 G 6.84 1.17 X 10-05 
12 rs9669708 LOC253724 A 9.84 1.19 X 10-05 
16 rs1428759 CNTNAP4 A 6.78 1.53 X 10-05 
16 rs1428758 CNTNAP4 G 6.61 1.74 X 10-05 
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2.3.4 Novel CCT candidate variants and their effect on POAG risk 
We selected 50 SNPs most strongly associated with CCT from the GWAS results 
based on a p-value cut off of 1 X 10-4 and tested these for association with POAG risk 
using the overall NEIGHBOR/GLAUGEN meta-analysis and meta-analyses stratified by 
intraocular pressure . Using a significance threshold of p < 0.001 (Bonferroni correction 
of 0.05/50), one SNP at the NTM gene locus (rs7481514, odds ratio (OR) = 1.28, p = 0.001) 
was significantly associated with POAG in the low tension subset (Table 4). As expected, 
each copy of the minor allele is associated with reduced CCT and an increased risk of 
POAG. A second SNP at the NTM locus was marginally associated in the low tension 
subset (rs7108536, OR = 1.25, p = 0.002). The two NTM SNPs are in high linkage 
disequilibrium (r2 = 0.87). An additional five SNPs at the CNTNAP4 gene showed 
suggestive association, although they did not meet the multiple testing corrected 
significance level (Table 4).  
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Table 4: Top ten SNPs associated with POAG in the low tension subset 
The top ten SNPs most associated with POAG out of the 50 candidate SNPs selected 
from the CCT GWAS are shown. The beta (µm) and odds ratio (OR) represent the effect 
size for each copy of the minor allele, given in the allele column. 
 
    
CCT  
association 
(N = 1,117) 
POAG 
association 
(N = 4,086) 
SNP Locus Chr. Allele Beta p OR p 
rs7481514 NTM 11 A -6.89 1.03 X 10-5 1.28 0.001 
rs7108536 NTM 11 G -6.78 1.00 X 10-5 1.25 0.002 
rs1428758 CNTNAP4 16 G 6.61 1.74 X 10-5 0.84 0.018 
rs9939043 CNTNAP4 16 A 7.15 2.70 X 10-6 0.85 0.022 
rs6701037 TNN 1 C -6.11 3.31 X 10-5 0.85 0.024 
rs4959388 LY86-AS1 6 G 7.07 1.85 X 10-5 1.18 0.031 
rs1109739 16q12 16 A -8.48 4.13 X 10-5 0.81 0.038 
rs2866710 CNTNAP4 16 G 6.84 1.17 X 10-5 0.86 0.051 
rs2052866 CNTNAP4 16 A 6.51 3.27 X 10-5 0.86 0.054 
rs1428759 CNTNAP4 16 A 6.78 1.53 X 10-5 0.87 0.072 
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The most significant CNTNAP4 SNP was rs1428758 (OR = 0.84, p = 0.018). The 
strong linkage disequilibrium in this region (Figure 2) suggests these signals are 
probably not independent. The effects of these five SNPs are also in the expected 
direction; each copy of the minor allele is associated with an increase in CCT and a 
protective effect on POAG risk. No SNP was associated with POAG in the overall 
dataset or the high tension subset. 
 
 
Figure 2: Linkage disequilibrium of the five CNTNAP4 SNPs identified in the 
low tension subset 
Linkage disequilibrium is given in r2 calculated in Haploview. 
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2.3.5 Gene expression analysis of candidate genes 
We evaluated CNTNAP4 and NTM gene expression in human adult and fetal 
brain, optic nerve, cornea and sclera tissues (Figure 3). CNTNAP4 was expressed in adult 
brain, optic nerve, and cornea, but we found no evidence of CNTNAP4 expression in the 
adult sclera sample. Similarly, we found evidence of CNTNAP4 expression in the fetal 
brain, optic nerve, and cornea tissues, but not in the fetal sclera sample. We showed 
NTM expression in all of the tissues examined in both the adult and fetal stage tissues 
(Figure 3). 
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Figure 3: Evidence of CNTNAP4 and NTM gene expression in adult and fetal 
ocular tissue samples 
The figure shows the resulting agarose gel image from the gene expression 
assays of CNTNAP4 (top), NTM (middle), and GAPDH (lower) expression in brain and 
ocular tissue samples. The lanes from left to right contain size standard ladder (L; band 
sizes 100, 200, 400, 800, 1200, and 2000 base pairs), adult brain (A-B), adult optic nerve 
(A-ON), adult cornea (A-Cor), adult sclera (A-Scl), fetal brain (F-B), fetal optic nerve (F-
ON), fetal cornea (F-Cor), and fetal sclera (F-Scl). 
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2.4 Discussion 
CCT is an important quantitative risk factor for POAG, but whether CCT directly 
influences POAG susceptibility remains unknown. One way to improve our 
understanding of this relationship is to identify genes that are associated with both 
traits. In this study, we replicated the association of previously published CCT genetic 
variants in a POAG population and showed that despite the well-established genetic 
association observed between these loci and CCT, there was no evidence that they 
influence POAG risk. We have also identified two POAG candidate genes, NTM and 
CNTNAP4, first by association with CCT and second by association analysis with POAG 
risk. These genes are good biological candidates for future research in the etiology of 
POAG.  
In our dataset, POAG cases have significantly lower mean CCT compared to 
controls and within the POAG cases, the low tension subset have significantly lower 
mean CCT compared to the high tension subset. Consistent with our results, several 
studies have suggested CCT is reduced in normal tension glaucoma as compared with 
POAG (Kniestedt, Lin et al. 2006; Sullivan-Mee, Halverson et al. 2006; Kaushik, Pandav 
et al. 2012). One possible explanation for this observation is that thinner corneas may be 
representative of a thinner, weaker posterior eye structure, which may increase 
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susceptibility to optic nerve stress caused by elevated or fluctuating intraocular 
pressure.  
In this study, we investigated the effects of previously published CCT SNPs and 
replicated the association of rs12447690 near the ZNF469 gene, an uncharacterized zinc-
finger protein (Lu, Dimasi et al. 2010; Vitart, Bencic et al. 2010; Vithana, Aung et al. 
2011). Mutations in this gene are known to cause brittle cornea syndrome, a systemic 
connective tissue disorder characterized by a high risk of corneal tearing (Abu, Frydman 
et al. 2008). The association of this SNP with CCT has been replicated in multiple 
populations, and there is strong evidence that this gene is involved with normal CCT 
variation (Lu, Dimasi et al. 2010; Vitart, Bencic et al. 2010; Vithana, Aung et al. 2011). 
SNPs within two genes, COL5A1 and IBTK, were previously identified in multiple 
population-based CCT studies (Vitart, Bencic et al. 2010; Cornes, Khor et al. 2011; 
Vithana, Aung et al. 2011). We also found evidence that these SNPs are associated with 
CCT in our primarily POAG case population. COL5A1 is a logical candidate gene for 
cornea thickness variation as the corneal stroma is largely composed of regularly 
arranged collagen fibers. Mutations in this gene have been identified in Ehlers-Danlos 
syndrome patients who have reduced cornea thickness (Segev, Heon et al. 2006). IBTK 
was recently identified in a CCT meta-analysis conducted in a multi-ethnic Asian 
population cohort study (Cornes, Khor et al. 2011). This group hypothesized that IBTK 
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may regulate corneal thickness during developmental stages and embryogenesis 
through its negative regulation of BTK kinase activity or its effect on nuclear factor-
kappa-B (NF-κB) activation.   
We were unable to replicate association of the remaining 16 published CCT SNPs 
with CCT. This may be due to the limited sample size of our CCT dataset (N = 1,117). 
We had an estimated 66% power, assuming a minor allele frequency of 0.25 and an 
effect of -6.00 ∆ CCT (µm/allele) (Gauderman WJ 2006), to detect association with CCT. 
Thus, based on this estimate, we cannot rule out false negative findings for those 16 loci. 
However, we also examined the potential association of all 20 CCT-associated loci with 
POAG in our dataset and found no evidence that any of these well-established CCT 
genes results in increased POAG susceptibility. We would expect that the overall POAG 
dataset has greater power to detect genotypic effects because of the increased sample 
size (N = 6,470), although the true power of this dataset is unknown because the putative 
effect sizes of these loci on POAG risk remain unknown.  
In our CCT GWAS, no SNPS met genome-wide significance thresholds. As with 
the replication analysis, this may be due to a lack of statistical power resulting from 
sample size limitations or due to the fact that our study population consists mainly of 
POAG cases which may have different genetic determinants of CCT than population 
controls.  
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 To determine if any of the top SNPs identified in our CCT analysis also influence 
POAG risk, we tested selected candidates SNPs for association with POAG in the overall 
dataset and two subsets, low tension and high tension, stratified by a history of elevated 
intraocular pressure. Stratification by intraocular pressure may provide a more clinically 
homogenous population resulting in reduced genetic heterogeneity within the dataset. 
In the low tension subset of POAG cases, neurotrimin (NTM) was significantly 
associated with increased POAG risk and, as expected, also a decrease in CCT. The size 
of these effects is consistent with published reports suggesting a decrease of 40 µm of 
CCT is associated with a 1.7-fold increased risk of POAG (Gordon, Beiser et al. 2002). 
NTM is a member of the immunoglobulin domain-containing IgLON superfamily of 
glycosyl-phosphatidylinositol (GPI)-anchored cell adhesion molecules. NTM can be 
found in both membrane-bound and soluble forms and has known roles in mediating 
cell-cell interactions and regulating neurite outgrowth (Struyk, Canoll et al. 1995; Gil, 
Zanazzi et al. 1998; Lodge, McNamee et al. 2001). It has high homology with the well 
characterized neuronal cell adhesion molecule (NCAM), which has also been shown to 
have a role in neurite outgrowth. NCAM was found to be constitutively expressed in 
human corneal endothelium cells, although the role of neuronal cell adhesion molecules 
within the cornea remains unknown (Foets, van den Oord et al. 1992). Previous reports 
found NTM to be expressed during development, continuing into adulthood, and 
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abundant expression has been observed in the ganglion cell layer of the retina (Struyk, 
Canoll et al. 1995). It is possible that NTM plays a role in glaucoma susceptibility by 
influencing neuron outgrowth during development. Therefore, we examined the 
presence of NTM expression in relevant tissues from a developing fetus and found NTM 
is expressed in the brain, optic nerve, cornea, and sclera with similar expression 
observed in the adult sample. We included an adult brain sample as a positive control 
since it has been shown that NTM is expressed primarily in the central nervous system 
(Struyk, Canoll et al. 1995). This expression work provides further evidence that NTM is 
a viable candidate for future POAG research. 
We have also identified contactin-associated protein-like 4 (CNTNAP4) as a 
candidate gene for glaucoma risk in the low tension POAG subset. Although the 
statistical evidence for association with this gene is modest, like NTM, it is a neural cell 
adhesion molecule and is important in cell-cell interaction within the nervous system 
(Spiegel, Salomon et al. 2002). CNTNAP4 is located within a region linked to 
keratoconus, a disease defined by the progressive thinning of the cornea (Tyynismaa, 
Sistonen et al. 2002). In addition, SNPs within CNTNAP2, a gene closely related to 
CNTNAP4, has previously been associated with pseudoexfoliation glaucoma 
(Krumbiegel, Pasutto et al. 2011; Liu and Allingham 2011). We have shown that 
CNTNAP4 is expressed in the brain, optic nerve, and cornea during development and in 
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adulthood. Together, NTM and CNTNAP4 suggest that neural cell adhesion molecules 
could constitute a novel pathway relating reduced CCT to POAG risk.  
As part of an international effort to better understand the genetics of CCT and its 
effect on POAG risk, a large CCT meta-analysis was performed on > 20,000 individuals 
and utilized the CCT genetic data generated as part of this study (Lu, Vitart et al. 2013). 
The meta-analysis (conducted using two non-glaucomatous population-based datasets 
with 13,057 European individuals and 6,963 Asian individuals) resulted in the 
identification of over 20 loci significantly associated with CCT at the genome-wide 
significance threshold. Similar to the approach used in this study, CCT variants 
identified in the international meta-analysis were tested for association with CCT within 
the NEIGHBOR/GLAUGEN datasets and then tested for association with POAG risk. 
The results of that analysis were consistent with the results presented here; CCT-
associated variants identified by the international meta-analysis were, in general, 
associated with CCT in the POAG dataset, suggesting that variants that influence CCT 
are the same in diseased (POAG) and non-diseased populations. Likewise, these 
variants were not associated with POAG risk. Since the cutoffs for candidate SNP 
selection used in these studies are somewhat arbitrary, we applied a polygenic modeling 
approach which calculates a risk score given a range of p-value cutoffs, as previously 
described (Purcell, Wray et al. 2009). The goal of this approach is to determine if the 
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combined effects of SNPs identified in the CCT meta-analysis can predict POAG risk4. 
However, there was little evidence that the aggregate effects of CCT accurately 
predicted POAG risk. This calls into question the true POAG endophenotype status of 
CCT. In agreement with these findings, Charlesworth et al. observed a significant 
phenotypic correlation between CCT and POAG, but no genotypic correlation, and 
determined CCT is not likely a true POAG endophenotype (Charlesworth, Kramer et al. 
2010).  
However, this highlights the importance of disease specific datasets and proper 
stratification by relevant clinical variables, such as intraocular pressure. CCT and POAG 
may have a shared genetic relationship, as suggested by the potential association of 
genes identified in a CCT GWAS restricted to POAG cases. Like many other quantitative 
traits, it is likely to be mediated by many common loci of modest effect sizes. Rare 
variants within the CCT loci may result in profound structural changes in the cornea, 
but more common variants might produce the CCT variation that is observed on a 
population level. Our study suggests that these common variants are not associated with 
POAG. Nonetheless, CCT genomics research may offer promise to reveal new insight 
into the genetic architecture of a subset of POAG cases, as suggested by the potential 
                                                   
4 The polygenic modeling analyses for the NEIGHBOR and GLAGUEN datasets was conducted by Megan 
Ulmer Carnes at the Duke Center for Human Genetics as described in the original manuscript, Lu, Y., V. 
Vitart, et al. (2013). "Genome-wide association analyses identify multiple loci associated with central corneal 
thickness and keratoconus." Nat Genet 45(2): 155-163. 
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association of genes within neuronal cell adhesion pathways. However, it may be more 
immediately advantageous to use CCT in the clinical prediction of POAG development, 
since its association with POAG is well-established and it is an easily measureable trait. 
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3. Discovery and functional annotation of SIX6 variants 
in POAG
1
  
3.1 Introduction 
The NEI Glaucoma Human Genetics Collaboration (NEIGHBOR) and the 
Glaucoma Genes and Environment (GLAUGEN) consortia identified a significant 
genetic association at the SIX1/SIX6 locus (rs10483727, OR = 1.32, p = 3.87X10-11) in a 
recently published POAG genome-wide association study (Wiggs, Yaspan et al. 2012). 
Variants in the SIX1/SIX6 locus were first associated with quantitative optic nerve 
parameters in non-diseased populations including vertical cup-disc ratio (VCDR), which 
is used clinically to diagnose and monitor POAG progression (Macgregor, Hewitt et al. 
2010; Ramdas, van Koolwijk et al. 2010). Several studies have independently confirmed 
the association of the SIX1/SIX6 locus with both VCDR and POAG (Fan, Wang et al. 
2011; Ramdas, van Koolwijk et al. 2011; Osman, Low et al. 2012).  
The human SIX gene family consists of six members (SIX1-SIX6), all of which 
contain two shared protein domains, a DNA binding homeobox domain and a SIX 
domain, which binds downstream effector molecules (Kawakami, Sato et al. 2000; 
Kumar 2009). Members of this highly conserved gene family function as transcription 
factors, regulating key developmental steps through a complex regulatory network, 
                                                   
1 A modified version of this chapter is published as M Ulmer Carnes, et al. (2014). “Discovery and functional 
annotation of SIX6 variants in primary open-angle glaucoma.” PLOS Genetics. In print. 
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were originally identified through homology to the Drosophila sine oculis (so) gene, 
which is required for proper eye development (Kawakami, Sato et al. 2000; Kumar 2009). 
During embryonic development, SIX1 is broadly expressed in multiple tissues including 
the otic vesicle, limb mesenchyme, and others. However, expression of SIX6 is primarily 
restricted to regions of the retina and the pituitary (Kawakami, Sato et al. 2000; Conte, 
Marco-Ferreres et al. 2010). Drosophila with null so alleles have restricted retinal 
development, and Iglesias et al. recently demonstrated that morpholino knockdown of 
six6b in zebrafish embryos results in a small eye phenotype (Kawakami, Sato et al. 2000; 
Iglesias, Springelkamp et al. 2013). In humans, a large deletion on chromosome 14q22.3-
q23 that includes SIX6 causes bilateral anophthalmia, the absence of both eyes, 
demonstrating the importance of SIX gene family members in ocular development and 
human disease (Cheyette, Green et al. 1994; Gallardo, Lopez-Rios et al. 1999; Kawakami, 
Sato et al. 2000; Kenyon, Yang-Zhou et al. 2005; Kumar 2009). 
In this study, we have extended the current understanding of the molecular 
contributions of SIX6 to POAG risk in several ways. First, we identified potential POAG 
risk alleles by sequencing the SIX6 gene in a case-control dataset. We found both 
common and rare coding changes within the SIX6 gene in POAG cases, as well as 
sequence variants in the SIX6 enhancer. We then used the zebrafish system to 
demonstrate that these human coding variants have functional consequences in eye 
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development. This analysis of 2-3 day old zebrafish embryos is not intended to fully 
recapitulate the glaucomatous phenotype; however, it provides valuable in vivo data 
about the functional effects of human genetic variation. We next used luciferase reporter 
assays to show that a sequence variant found in the SIX6 enhancer of glaucoma patients 
may increase SIX6 expression. We also demonstrate, for the first time, that POAG cases 
homozygous for the SIX6 risk allele rs33912345 have a statistically significant thinner 
global retina nerve fiber layer. 
3.2 Material and methods 
3.2.1 Subjects 
Study subjects were unrelated patients from the Duke Eye Center and, after a 
comprehensive eye examine, were classified as either POAG cases or controls2. POAG 
cases presented with glaucomatous optic neuropathy, defined as a cup-disc ratio greater 
than 0.7 and visual field loss in at least one eye. Patients with secondary forms of 
glaucoma or a history of ocular trauma were excluded from the study. POAG controls 
had no evidence of optic neuropathy, normal intraocular pressure (less than 22 mm Hg 
in both eyes), and normal visual fields, assessed using standard automated perimetry. 
This research was approved by the Institutional Review Board of Duke University 
Medical Center and adheres to the tenets of the Declaration of Helsinki. 
                                                   
2 POAG patient diagnosis was performed at the Duke Eye Center by Dr. Rand Allingham. 
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3.2.2 DNA sequencing 
Genomic DNA was extracted from patient blood samples using the PureGene 
chemistry following the manufacturer’s standard protocol (Gentra, Minnesota, USA). 
The coding portions (2 exons) of the SIX1 and SIX6 genes were sequenced in 518 
Caucasian POAG cases and controls (262 cases, 256 controls) using a polymerase chain-
reaction (PCR) containing 1 X Qiagen PCR buffer (Tris·Cl, KCl, (NH4)2SO4, 15 mM 
MgCl2; pH 8.7); 200 µM each of dATP, dCTP, dGTP, and dTTP; 0.4 µM forward PCR 
primer; 0.4 µM reverse PCR primer; 3 µL of betaine, 10 ng genomic DNA; and 0.5 U 
HotStarTaq DNA polymerase (Qiagen, Limburg, Netherlands) to a final volume of 25 
µL3. Primer sequences are available in Appendix C. The PCR was performed using a 
touchdown protocol (incremental lowering of annealing temperature) using the 
following thermocycler conditions: 94˚C for 30 s, 65˚C for 30 s, 72˚C for 30 s with a 2˚C 
decrease in the annealing temperature every two cycles until a final annealing 
temperature of 55˚C was reached. The retinal specific SIX6 enhancer, previously 
described (Conte, Marco-Ferreres et al. 2010), was amplified a using a touchdown 
protocol with a final annealing temperature of 57˚C. PCR products were sequencing 
                                                   
3 DNA was extracted at the Duke DNA Bank. The coding portions of SIX1 and SIX6 were amplified by Dr. 
Benjamin Whigham and the SIX6 enhancer was amplified by Megan Ulmer Carnes. Sequencing was 
performed by Beckman Coulter Genomics (Danvers, MA, USA). 
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using the BigDye chemistry on a 3730 DNA Analyzer (Life Technologies, New York, 
USA). 
3.2.3 Genotyping and imputation 
The common missense SNP, rs33912345, was genotyped in the Duke POAG case-
control dataset consisting of 482 POAG cases and 433 POAG controls using a TaqMan 
allelic discrimination assay according to the standard protocols from the manufacturer4 
(Life Technologies). For quality control purposes, the following criteria were met: > 95% 
genotyping efficiency, matching sample duplicates (two Centre d'Etude du 
Polymorphisme Humain samples per 96-well plate whose genotype data matched across 
all plates), and Hardy-Weinberg equilibrium assumptions. We tested for association of 
rs33912345 with POAG using an additive logistic regression model adjusted for age and 
sex using SAS (SAS Institute Inc. 2002-2008). 
Genome-wide genotype data were available from the NEIGHBOR and 
GLAUGEN consortia (Wiggs, Yaspan et al. 2012). Chromosome 14 was imputed5 using 
IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) with a global 1000 
Genomes reference panel. We tested SNPs at the SIX1/SIX6 locus for association with 
POAG using an additive logistic regression model adjusted for age, sex, and four 
                                                   
4 Genotyping was performed by Dr. Benjamin Whigham at the Duke Center for Human Genetics. 
5 Imputation was completed by Melanie Garrett at the Duke Center for Human Genetics. 
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principal components (NEIGHBOR) or age, sex, study site, DNA extraction method, 
DNA specimen type and principal components 1-6 (GLAUGEN) implemented in PLINK 
and visualized using LocusZoom (http://csg.sph.umich.edu/locuszoom/) (Purcell, Neale 
et al. 2007; Pruim, Welch et al. 2010). A meta-analysis was performed in Plink using a 
random effects model. Linkage disequilibrium was calculated and visualized using 
Haploview (http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/haploview) 
(Barrett, Fry et al. 2005). 
3.2.4 Retinal nerve fiber layer thickness analysis 
Optical coherence tomography (OCT) measurements of retinal nerve fiber layer 
(RNFL) by Spectralis (Heidelberg Engineering, California, USA) spectral domain) and 
fundus photography were available from the Duke Eye Center6. OCT images are not 
routinely performed in patients without ocular disease, so there was limited data 
available for controls. Therefore, the analysis was restricted to POAG cases homozygous 
for rs33912345. Thirty patients had both OCT measurements and SIX6 genotype data. 
RNFL thickness, age at POAG diagnosis, and the age at OCT measurement were 
compared between individuals homozygous for the risk or non-risk allele using a 
Student’s t-test. Analyses were performed in SAS (SAS Institute Inc. 2002-2008). 
                                                   
6 OCT images were taken by clinicians at the Duke Eye Center and were compiled by Dr. Shane Havens.  
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3.2.5 Microinjection of morpholino and mRNA 
A vector containing human SIX6 was purchased from the CCSB Human 
ORFeome Collection that uses the Gateway technology system (Open Biosystems and 
Life Technologies). SIX6 alleles identified by sequencing (Glu93Gln, Glu129Lys, 
Asn141His, Leu205Arg, Thr212Met, and Ser242IIe) were created using the QuikChange 
II site-directed mutagenesis kit and protocols provided by the manufacturer (Agilent 
Technologies, California, USA). SIX6 mRNA was in vitro transcribed using the 
mMESSAGE mMACHINE SP6 Kit (Life Technologies). Translation blocking (TB) 
morpholinos against six6a and six6b (Appendix C) were purchased from Gene Tools, 
LLC (Oregon, USA). Morpholino (2 ng) and mRNA (12.5 pg) were mixed and a volume 
of 0.5 nL was microinjected into each wild-type zebrafish embryo at one- to eight-cell 
stage, as previously described (Stuart, McMurray et al. 1988)7. 
3.2.6 In vitro luciferase assay 
SIX6 enhancer alleles were tested using a dual-luciferase reporter assay system 
(Promega, Wisconsin, USA). An experimental construct containing a minimal promoter 
(pGL4.23, firefly luciferase, Promega) was used to test the functional effect of the 
enhancer alleles identified by sequencing (Chr14:60974363_C, Chr14:60974373_T, 
Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) in the POAG case/control 
                                                   
7 The in vivo zebrafish assay (morpholino design, microinjection, and ocular measurements) were performed 
by Drs. Edwin Oh and Yangfan Liu at the Duke Center for Human Disease Modeling. 
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dataset. The experimental constructs (pGL4.23+Enhancer) were generated using a nested 
PCR protocol (primers given in Appendix C); the XhoI and HindII enzymes; the Quick 
Ligation kit (New England BioLabs, Massachusetts, USA); and the QuikChange II site-
directed mutagenesis kit (Agilent Technologies), following protocols provided by the 
manufacturers. Constructs were confirmed to be correct by sequencing. Hek293 cells 
were cultured according to the supplier’s suggestions (ATCC, Virginia, USA). As 
described by Conte et al., co-transfection with NeuroD and E47 is required for SIX6 
enhancer activation (Conte, Marco-Ferreres et al. 2010). Therefore, cells were co-
transfected with an experimental vector (pGL4.23+Enhancer), a control vector (pGL4.74, 
renilla luciferase, Promega), and vectors containing NeuroD and E47 (provided by the 
Center for Human Disease Modeling, Duke University) using a standard calcium 
phosphate transfection protocol. The experiment was performed three times in triplicate, 
and the results were analyzed using the dual luciferase reporter (DLR) ratio (firefly 
luciferase sum: renilla luciferase sum) normalized by the reference SIX6 enhancer 
included on every plate. The data were analyzed using an ANOVA, adjusted for batch, 
and linear contrasts were used to determine the effect of each vector. Statistical analyses 
were performed in SAS (SAS Institute Inc. 2002-2008). 
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3.3 Results 
3.3.1 Identification of SIX6 risk alleles in POAG cases 
Sequencing of the SIX1 and SIX6 genes in Caucasian POAG cases and controls 
(262 cases, 256 controls) revealed the presence of 23 SNPs (Appendix D). Nine SNPs 
were identified in SIX1, but no nonsynonymous SNPs were identified in the POAG 
cases. Sequencing of SIX6 revealed the presence of 14 variants including five rare 
nonsynonymous SNPs in POAG cases and controls, one common nonsynonymous SNP 
located in the homeobox of SIX6 (rs33912345, Asn141His), and five sequence variants 
within the SIX6 enhancer (Table 5). 
  
Table 5: SIX6 variants identified by sequencing POAG cases and controls 
Locus Coordinates SNP ID 
MAF POAG 
Cases 
MAF POAG  
Controls 
Base Change 
AA 
Change 
Enhancer Chr14:60974363 ---- 0.002 0 G>C ---- 
Enhancer Chr14:60974373 rs8004739 0.008 0 C>T ---- 
Enhancer Chr14:60974378 ---- 0 0.002 C>T ---- 
Enhancer Chr14:60974400 ---- 0.002 0.002 C>A ---- 
Enhancer Chr14:60974449 ---- 0.002 0 A>G ---- 
SIX6 Chr14:60976393 rs78954112 0 0.002 G>C Glu93Gln 
SIX6 Chr14:60976501 rs146737847 0.008 0.002 G>A Glu129Lys 
SIX6 Chr14:60976537 rs33912345 0.47 0.37 A>C Asn141His 
SIX6 Chr14:60977843 rs45549246 0.002 0.002 T>G Leu205Arg 
SIX6 Chr14:60977864 rs202029915 0.002 0 C>T Thr212Met 
SIX6 Chr14:60977954 rs139302405 0.002 0 G>T Ser242Ile 
 MAF = minor allele frequency; AA = amino acid. Coordinates are given based on the Hg19 reference. 
4
7 
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Genotyping of rs33912345 in the Duke POAG case-control dataset (482 cases, 433 
controls) resulted in a significant association (OR = 1.40, p = 0.0005, POAG case minor 
allele frequency (MAF) = 0.47, POAG control MAF = 0.38) with POAG. This SNP is in 
high linkage disequilibrium (r2 = 0.95) with the intergenic SNP originally identified in 
POAG and VCDR genome-wide association studies (rs10483727) (Macgregor, Hewitt et 
al. 2010; Ramdas, van Koolwijk et al. 2010; Wiggs, Yaspan et al. 2012; Iglesias, 
Springelkamp et al. 2013). As expected, meta-analysis of the imputed genotype data 
from the NEIGHBOR and GLAUGEN studies confirmed a highly significant association 
between POAG status and rs33912345 (OR = 1.27, p = 4.2X10-10) and other strongly linked 
SNPs in the region (Appendix E). A closer look at this locus shows that the association 
signal includes both upstream and downstream regions of the SIX6 gene, while 
remaining entirely downstream of the SIX1 gene (Figure 4). 
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Figure 4: Plot of the association signal observed at the SIX1/SIX6 locus 
Plot shows the association results calculated using chromosome 14 imputed 
genotype data color coded by the r2 value with the index SNP, rs10483727 (designated in 
purple). 
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An analysis of retinal characteristics of POAG cases possessing the SIX6 risk and 
non-risk allele was performed using optical coherence tomography (OCT) (Table 6).  
OCT images were only available for POAG cases with the common SNP, rs33912345; no 
data were available for individuals with the rare SIX6 variants. We assessed retinal 
nerve fiber layer (RNFL) thickness in thirty POAG cases homozygous for the rs33912345 
risk allele (C) or the non-risk allele (A) first by comparing age at disease diagnosis and 
age at OCT across the two genotypes, because age is known to influence retinal 
thickness and is a potential confounder. No significant difference in age was observed (p 
= 0.11, p = 0.14, respectively). Next, RNFL thickness was evaluated. The overall thickness 
(global RNFL) was significantly reduced in cases homozygous for the risk allele 
compared to cases with the non-risk allele (p = 0.03; mean (SD): C = 58.3 (8.2) µm, A = 
67.9 (12.4) µm; Table 6), consistent with the hypothesis that SIX6 may increase POAG 
susceptibility via changes in the neural retina. To determine which quadrants were 
driving this observation, we performed an exploratory, post-hoc comparison of RNFL 
thickness in the temporal, nasal, inferior, and superior regions. Interestingly, RNFL 
thickness was significantly reduced in the inferior (p = 0.03) and superior (p = 0.04) 
quadrants, the two regions directly affecting VCDR measurements.  
  
51 
Table 6: OCT measurements from POAG cases homozygous for rs33912345 
Variable Allele N Mean (SD) p 
Age at POAG diagnosis (years) A 18 63.9 (9.1) 0.11 
 C 12 69.7 (10.2)  
Age at OCT measurement (years) A 18 71.2 (9.7) 0.13 
 C 12 76.9 (10.3)  
Nerve fiber thickness (µm): Global A 18 67.9 (12.4) 0.03 
 C 12 58.3 (8.2)  
Temporal A 18 57.2 (15.2) 0.85 
 C 12 56.2 (12.8)  
Nasal A 18 57.4 (13.4) 0.06 
 C 12 47.9 (12.8)  
Inferior A 18 79.6 (18.7) 0.03 
 C 12 65.2 (12.6)  
Superior A 18 77.0 (22.2) 0.04 
 C 12 63.9 (10.8)  
 
3.3.2 In vivo functional interrogation of SIX6 missense variants 
Given 1) the observed association signal pattern; 2) the lack of coding changes 
identified in SIX1; 3) the presence of rare missense variants and a common, highly 
associated missense SNP in SIX6; 4) retinal nerve fiber layer thickness changes observed 
in POAG cases homozygous for the SIX6 risk allele; and 5) the localized expression of 
SIX6 in ocular tissues, we concluded SIX6 is likely the better candidate gene in this 
region and evaluated the functional relevance of SIX6 using an in vivo zebrafish 
complementation assay.  
First, we performed a reciprocal BLAST analysis and identified two validated 
orthologs of SIX6 in the zebrafish genome, Six6a and Six6b, both with 91% homology at 
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the protein level. Previous overexpression and loss of function studies of SIX6 in mouse 
and frog models reveal a role in regulating the proliferative state of retinal progenitor 
cells and the size of the eye (Zuber, Perron et al. 1999; Li, Perissi et al. 2002); therefore, to 
evaluate whether the identified SIX6 variants are pathogenic and potentially relevant to 
POAG, we sought to ask whether 1) morpholino-induced suppression of six6a or six6b 
leads to a reduced eye size; 2) expression of the human SIX6 non-risk allele rescues the 
morphant eye phenotype; and 3) expression of SIX6 alleles containing POAG risk 
variants rescues the morphant eye phenotype. 
Using translation-blocking morpholinos targeting zebrafish six6a and six6b, we 
injected 1-8 cell stage embryos (N = 50-150) and analyzed live embryos at 3 days post 
fertilization (dpf). A translation-blocking morpholino was used because SIX6 is a two 
exon gene—splice-blocking morpholinos are generally not recommended for two exon 
genes as the targeted transcript will not be subject to nonsense mediated decay, possibly 
leading to the expression of a truncated protein and potential dominant-negative effects 
(described by the manufacturer: http://www.gene-tools.com/node/18). Masked scoring7 
of both six6a and six6b morphants revealed ocular phenotypes consistent with loss of 
function, including a reduction in eye size in more than 80% of embryos (p < 0.001, 
Figure 5). The specificity of the morpholino reagents was tested by co-injection of 12.5 
                                                   
7 Zebrafish morpholino optimization, mask scoring, and comparative analyses were performed by Drs. 
Edwin Oh and Yangfan Liu at the Duke Center for Human Disease Modeling. 
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pg of the human SIX6 non-risk allele mRNA and significant (p < 0.001) rescue was 
observed in six6a but not six6b morphant embryos (90% vs. 10% of embryos, 
respectively). Together, these data indicate that Six6a is the functional ortholog of 
human SIX6 and prompted subsequent evaluation of SIX6 variants using the six6a 
morpholino. 
 
 
Figure 5: Morpholino knockdown of six6a 
The figure highlights the reduction in eye size observed in zebrafish 
microinjected with a six6a translation blocking morpholino. Lateral images, taken 3 days 
post fertilization (3 dpf), of a wild-type zebrafish (left) and a morpholino injected 
zebrafish (right) are shown, highlighting the small eye phenotype (dashed circle). 
 
 
  
54 
To investigate the pathogenic potential of all SIX6 variants, we used total eye size 
and the rescue of the morphant phenotype as the assay’s phenotypic readout. We 
injected a mixture containing six6a morpholino and the various human SIX6 alleles 
containing the coding variants identified via sequencing (Table 5). These results were 
compared to the rescue condition of the human SIX6 non-risk allele. Five of the six 
variants tested were unable to fully rescue the small eye phenotype. Four of these alleles 
(Glu129Lys, Asn141His, Thr212Met, and Ser242Ile) resulted in an average eye size larger 
than the morpholino alone (p < 0.001), but smaller than the rescue with the non-risk 
allele (p < 0.001), indicating that these alleles are hypomorphic (Figure 6, Table 7). We 
also observed one variant (Leu205Arg) with an average eye size smaller than the 
morpholino alone (p = 0.002; mean (SD): MO = 34,042 (5,763) µm, Leu205Arg = 31,568 
(6,485) µm; Figure 6), suggesting that it may be functionally null. One allele (Glu93Gln) 
resulted in an eye size similar to the rescue with the non-risk allele (p = 0.37) and was 
determined to be benign. The benign allele was identified in one control individual, 
while the remaining hypomorphic and null alleles were identified either exclusively or 
primarily in POAG cases (Table 5). Injection of 12.5 pg of the human SIX6 risk mRNA 
into non-morphant zebrafish provided no evidence of a toxic gain of function compared 
to injection with the non-risk allele.   
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Figure 6: Results from an in vivo zebrafish morpholino assay showing the effects of 
SIX6 nonsynonymous variants indentified in POAG cases and controls 
The plot shows that compared to the uninjected controls, morphants have a significant 
reduction in eye size (µm2). Zebrafish were co-injected with a translation blocking 
morpholino designed to target six6a and human SIX6 alleles (Glu93Gln, Glu129Lys, 
Asn141His, Leu205Arg, Thr212Met, or Ser242IIe). Results of each allele 
were compared to the SIX6 non-risk allele (Ref). P-values are provided below  
the mean of each treatment. 
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Table 7: Results from the in vivo zebrafish six6a morpholino assay showing 
changes in total eye size 
The effect on eye size, given as mean µm2 (standard deviation (SD)), was measured for 
wild-type zebrafish (Control) and zebrafish injected with a six6a morpholinos and SIX6 
alleles identified by sequencing POAG cases and controls. Each treatment was compared 
to the zebrafish injected with the human SIX6 non-risk allele (Ref).  
Treatment N Mean eye size, µm2 (SD) p 
Uninjected Control 146 53,140 (4,536) <0.0001 
Translation 
Blocker 
Morpholino 153 34,042 (5,763) <0.0001 
Human SIX6 Non-risk allele 177 49,040 (11,652) Ref 
Glu93Gln Variant allele 92 50,010 (5,893) 0.37 
Glu129Lys Variant allele 100 44,719 (6,791) <0.001 
Asn141His Variant allele 129 43,150 (10,660) <0.0001 
Leu205Arg Variant allele 101 31,568 (6,485) <0.0001 
Thr212Met Variant allele 84 38,278 (7,244) <0.0001 
Ser242IIe Variant allele 88 38,420 (7,310) <0.0001 
 
3.3.3 In vitro functional interrogation of SIX6 enhancer variants 
We hypothesized that POAG risk may be mediated not only by defects in SIX6 
protein function, but also by the level of SIX6 gene expression. To test this, we 
sequenced the SIX6 retinal specific enhancer element in 262 POAG cases and 256 POAG 
controls and identified 5 variants (Chr14:60974363_C, Chr14:60974373_T, 
Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) (Table 5). The effect of these 
variants on expression was tested using an in vitro luciferase assay. Of the five variants 
tested, one (Chr14:60974449_G) resulted in a significant increase in expression compared 
to the reference enhancer (Figure 7). Activation of the SIX6 enhancer requires two 
cofactors, NeuroD and E47 (Figure 8) (Conte, Marco-Ferreres et al. 2010). 
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Overexpression was observed with the Chr14:60974449_G variant even in the absence of 
these cofactors (Figure 9), suggesting variants within the enhancer region may result in 
dysregulated protein expression. 
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Figure 7: In vitro luciferase assay results showing the effects of SIX6 enhancer 
variants identified in POAG cases and controls 
SIX6 enhancer alleles were tested using a dual luciferase assay and the ratio of the 
experimental luciferase: control luciferase was calculated (DLR ratio). All vectors were 
co-transfected with NeuroD and E47. In this context, the SIX6 enhancer is functioning to 
increase expression compared to the empty vector (pGL4.23), driven by a minimal 
promoter. Compared to the reference enhancer (Ref), one variant (Chr14:60974449_G) 
significantly increases the enhancer’s activity. Coordinates are based on the Hg19 
reference. P-values are provided below the mean of each vector. 
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Figure 8: In vitro luciferase assay results from the SIX6 enhancer co-transfected with 
NeuroD and E47 
The SIX6 enhancer alone was inactive compared to the empty vector (pGL4.23). Co-
transfection of both NeuroD and E47 significantly increased the enhancer’s activity. The 
highest activity level was reached with co-transfection of an equal amount of both, as 
previously described (Conte, Marco-Ferreres et al. 2010). P-values are provided below 
the mean of each vector. 
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Figure 9: In vitro luciferase assay results from the SIX6 enhancer variants 
without co-transfection with NeuroD and E47 
In the absence of NeuroD and E47, the SIX6 enhancer is not active (Ref compared 
to the empty vector, pGL4.23). However, the Chr14:60974449_G variant still shows 
increased enhancer activity. Coordinates are based on the Hg19 reference. P-values are 
provided below the mean of each vector. 
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3.4 Discussion 
The SIX1/SIX6 locus has been shown to be significantly associated with POAG in 
several independent studies; however, the causal variant(s) driving this association have 
remained unknown (Ramdas, van Koolwijk et al. 2010; Fan, Wang et al. 2011; Ramdas, 
van Koolwijk et al. 2011; Osman, Low et al. 2012; Wiggs, Yaspan et al. 2012; Iglesias, 
Springelkamp et al. 2013). We have demonstrated through several lines of evidence—the 
tissue specificity of the SIX gene family described in the literature, the identification of 
SIX6 missense variants in our POAG dataset, and the results of the in vivo and in vitro 
assays— that SIX6 is the most likely POAG susceptibility gene in this region. We 
identified common and rare coding variants, which alter the function of the SIX6 
protein. We also identified a novel variant within the SIX6 enhancer that appears to 
disrupt the normal regulation of SIX6 expression, suggesting both regulatory and coding 
variants may influence POAG susceptibility at this locus. Finally, we are the first to 
identify clinical features in POAG patients that may be dependent upon SIX6 genotype:  
patients who are homozygous for the SIX6 risk allele have a statistically thinner retinal 
nerve fiber layer than patients homozygous for the SIX6 non-risk allele.   
The common variant, rs33912345 (Asn141His), which we showed has 
significantly reduced function in an in vivo model, was associated with POAG in our 
dataset and is in high linkage disequilibrium with the originally identified GWAS SNP, 
rs10483727 (Wiggs, Yaspan et al. 2012). This highly conserved amino acid is located 
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within the alpha helix structure of the DNA homeobox domain of SIX6. Interestingly, 
the ancestral allele (C, His) is associated with POAG risk. The allele frequency of this 
variant differs greatly among populations (C allele frequency: YRI (0.99), ARF (0.96), 
ASN (0.76), and CEU (0.42); from 1000 Genomes release 14) (Abecasis, Auton et al. 2012). 
This locus is significantly associated with an increase in vertical cup-disc ratio (VCDR) 
in population controls, indicating that it may be involved in the normal development of 
the optic nerve. VCDR is also a clinical measure used to track disease progression in 
POAG patients (Charlesworth, Kramer et al. 2010; Macgregor, Hewitt et al. 2010; 
Ramdas, van Koolwijk et al. 2010; Ramdas, van Koolwijk et al. 2011; Iglesias, 
Springelkamp et al. 2013). Interestingly, African populations have larger VCDRs and an 
increase in overall POAG prevalence (Girkin 2008; Girkin, Sample et al. 2010; Knight, 
Girkin et al. 2012). In a recent population-based study, the prevalence of POAG in 
Ghana exceeded 17%, the highest rate observed anywhere in the world (Budenz, Bandi 
et al. 2012). While rs33912345 is not associated with POAG risk in a West African POAG 
case/control dataset from Ghana, the frequency of the ancestral (risk) allele is 99% in 
both cases and controls (Liu, Hauser et al. 2013). We hypothesize that differences in the 
structure of the optic nerve and the higher risk of POAG in individuals with African 
ancestry may, in part, arise from the fact that essentially all individuals in this 
population are homozygous for the rs33912345 ancestral risk allele.  
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Given the association of the SIX6 locus with neural retinal measurements such as 
VCDR, it is reasonable to hypothesize causal variants may function by inducing 
quantitative changes in cell populations in the retina. There is extensive evidence that 
SIX6 regulates early retinal progenitor cell proliferation during eye development (Zuber, 
Perron et al. 1999; Bernier, Panitz et al. 2000; Li, Perissi et al. 2002). Li et al. showed that 
Six6-/- mice display varying degrees of retinal hypoplasia that is due to a decrease in 
retinal ganglion cell proliferation resulting from an early exit from the cell cycle during 
development (Li, Perissi et al. 2002). This is consistent with functional studies of XOptx2, 
the Xenopus ortholog of SIX6 (Zuber, Perron et al. 1999). We have shown a reduction in 
eye size upon morpholino knockdown of zebrafish six6a, and we were able to rescue this 
phenotype with co-injection of the human SIX6 non-risk allele, demonstrating that the 
zebrafish six6a gene is the likely functional ortholog to human SIX6. We identified five 
alleles that could not fully rescue the small eye phenotype, and we observed a reduction 
in retinal nerve fiber layer thickness in POAG patients homozygous for the His141 SIX6 
risk allele. Taken together with previously published findings, our results suggest that 
risk variants in the human SIX6 gene increase POAG susceptibility by negatively 
affecting retinal ganglion cell development, leading to a reduction in the number of 
retinal ganglion cells in adulthood. Retinal ganglion cells are lost during the normal 
aging process, and this rate of loss could be increased by the presence of additional 
glaucoma risk alleles or other risk factors such as increased intraocular pressure (Calkins 
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2013). The development of glaucomatous optic neuropathy and associated visual field 
loss would be hastened by a reduction in the initial number of retinal ganglion cells that 
an individual possesses.   
While the role of SIX6 in development is well established, it remains unclear 
what function SIX6 may have in adult tissues. SIX6 may increase POAG susceptibility 
through an unknown role in neuron maintenance. Consistent with this hypothesis, our 
study results show that rare and common variants within the SIX6 gene result in a loss 
of protein function and that changes in the SIX6 regulatory region result in aberrant 
expression. This and other SIX6 variants could increase the risk of glaucoma by 
increasing the rate of RGC death, as well as by reducing the initial number of retinal 
ganglion cells.   
In this study, we have identified multiple common and rare SIX6 sequence 
variants in POAG cases, and used in vivo and in vitro assays to demonstrate that these 
variants have functional consequences on SIX6 gene expression and protein function. 
While other risk factors may be required for the onset of POAG, we hypothesize that 
changes to SIX6 protein function increase an individual’s susceptibility to developing 
the disease via changes to retinal development. Additional work is needed, possibly 
through the use of transgenic animal model studies, to fully understand the role of SIX6 
in POAG. However, this is the first study to demonstrate clinical differences in POAG 
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patients carrying SIX6 risk alleles and to perform a functional analysis of alleles 
identified in POAG cases. 
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4. The transcriptional landscape of POAG-related tissues: 
the trabecular meshwork, cornea, and ciliary body 
4.1 Introduction 
Normal vision requires the proper development of and a synergistic relationship 
between various tissues. The trabecular meshwork (TM) and ciliary body (CB) tissues 
are of particular interest to the field of glaucoma due to their role in intraocular pressure 
regulation, the primary glaucoma risk factor (Kwon, Fingert et al. 2009). Additionally, 
the cornea is an extraordinarily important tissue for normal vision, as it is responsible 
for the majority of light refraction, and for glaucoma, because a reduction in corneal 
thickness is associated with an increased risk of developing POAG, discussed in detail in 
Chapter 2. There are many corneal diseases including keratoconus, brittle cornea 
syndrome, and Fuchs corneal dystrophy. Therefore, understanding corneal biology is 
fundamentally important. 
Some of the most basic biological questions can be answered by looking at the 
transcriptome, or the overall collection of RNA molecules within a cell or tissue. By 
global gene expression profiling, transcriptome analysis provides information about the 
inner workings of the cell type or tissue being studied. To date, a number of studies 
have investigated gene expression profiles of ocular tissues. However, previous studies 
have primarily been limited to microarray-based technologies (Liton, Luna et al. 2006; 
Turner, Budak et al. 2007; Janssen, Gorgels et al. 2012; Janssen, Gorgels et al. 2013; Liu, 
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Allingham et al. 2013). Microarray analysis is a hybridization-based approach that 
requires the transcriptional targets to be predefined. Transcriptional analysis via RNA 
sequencing (RNA-seq) is becoming increasingly popular because, unlike standard 
microarrays, there is a reduced need for a priori biological knowledge. RNA-seq can be 
used to identify the gene expression level of both known and novel transcripts. 
 In this study, we performed deep RNA sequencing of human adult and fetal 
ocular tissues samples to develop the first unbiased glimpse into the transcriptional 
landscape of the trabecular meshwork, cornea, and ciliary body tissues. We provide a 
basic descriptive analysis that gives insight into the related biology. We also use this 
data to investigate the gene expression levels and the presence of novel isoforms in 
POAG candidate genes identified by genome-wide association studies. This could easily 
be extended to additional ocular disease genes. Thus, this dataset is broadly applicable 
for ocular research. 
4.2 Materials and methods 
4.2.1 Sample selection 
Ocular samples were available from the North Carolina Eye Bank 
(https://www.nceyebank.org/) (Winston-Salem, North Carolina, USA). De-identified 
medical records were available and included age, race, sex, postmortem delay, primary 
and secondary cause of death, and a history of ocular disease (yes or no). Limited ocular 
medical records were available. Without the ability to properly phenotype individual 
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samples, we chose to select only samples with no known history of ocular disease. Two 
fetal samples and four adult samples were selected for transcriptome analysis (Table 8) 
based on the following criteria: no known history of ocular disease, matching age and 
sex, and Caucasian ancestry. 
4.2.2 RNA purification and sequencing 
The North Carolina Eye Bank procured the tissue samples and treated whole 
globes with RNAlater (Qiagen, Limburg, Netherlands) in order to preserve the RNA 
integrity. The globes were then dissected by an ophthalmologist1, and the individual 
tissues were re-treated with RNAlater by incubation at 4°C for 24 hours. The samples 
were then removed and stored at -80°C until the RNA extraction was performed.  
Tissues were homogenized using pre-sterilized tubes containing hard tissue 
grinding mix (Omni International, California, USA) in an Omni Bead Ruptor 24 using 
the following settings: 5.5 m/s, 15 sec, 2 cycles, D = 15 sec. RNA was then extracted from 
each tissue sample using the mirVana total RNA extraction kit (Ambion, Texas, USA), 
following the manufacturer’s protocol. The ciliary body is highly pigmented and 
melanin co-segregates with RNA during the isolation process, inhibiting downstream 
reactions (Dorrie, Wellner et al. 2006). Therefore, the ciliary body tissues went through a 
melanin removal processes modified from a previously published protocol 
(Satyamoorthy, Li et al. 2002). P-60 exclusion chromatography beads (Bio-Gel, 
                                                   
1 Dr. Rand Allingham (Duke University Eye Center) performed the tissue dissections from whole eyes. 
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California, USA) were prepared as described. Then, 800 µL of the prepared beads were 
placed in a Micro Bio-Spin chromatography column (Bio-Rad, California, USA). RNA 
was applied to the column, incubated for 10 minutes on ice, and centrifuged at 1000 rpm 
for 1 minute, keeping the RNA containing flow-through. To elute the remaining RNA, 
this process was repeated using 100 µL of diethylpyrocarbonate (DEPC) treated 10 mM 
sodium acetate. 
 RNA from each sample was DNAase treated using the DNA-free kit (Life 
Technologies, New York, USA). Subsequently, the quality was assessed using a chip-
based technology (RNA 6000 pico kit) on a 2100 Bioanalyzer (Agilent Technologies, 
California, USA) and was determined to be high quality (mean RNA integrity number 
(RIN) score = 8.5; min. RIN = 7.3; max. RIN = 8.7).  
RNA libraries were prepared using the TruSeq RNA sample preparation kit 
(Illumina, California, USA) and sequenced on four lanes of an Illumina HiSeq at the 
Duke Genome Sequencing and Analysis Core2. Samples were randomized across library 
preparation batches, barcoded, and randomized across sequencing lanes to reduce 
technical variability. The sequencing was determined to be high quality; all 12 samples 
had reads with mean quality scores (Q) > 37 and 94.5% or more reads with a Q > 30. The 
total number of paired reads per sample ranged from 32,137,380 to 59,784,117. 
                                                   
2 The TruSeq RNA library preparation and sequencing was performed by members of the Duke Genome 
Sequencing and Analysis Core. 
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4.2.3 Transcriptome analysis 
First, sequencing reads were checked for quality using the fastqc program, 
specifically looking at per base sequencing quality and overrepresented sequences (a list 
of programs used in the transcriptome analysis can be found in Appendix F). Based on 
these results, Illumina adapter sequences were trimmed using the cutadpat program 
(Martin 2011). The transcriptome was assembled using the Tuxedo package pipeline 
(Trapnell, Pachter et al. 2009). Pre-indexed human genome reference sequences 
(Ensembl build GRCH37) were downloaded from the TopHat website 
((http://tophat.cbcb.umd.edu/igenomes.shtml) and were used in all subsequent analyses. 
Reads were mapped using TopHat using the default parameters with the following 
adjustments: the library distribution mean, based on trace files provided by the 
sequencing center, was set to 250 bp (--mate-inner-dist) with a standard deviation of 100 
bp (--mate-std-dev 100) and 3 mismatching base pairs per read were allowed (--read-
mismatches, --read-edit-dist). The reference transcriptome was used in the initial 
alignment step (-G). The alignment was quality control checked by calculating the 
overall alignment rate and the percentage of properly paired mates using samtools (Li, 
Handsaker et al. 2009). The TM tissues had an average alignment rate of 97.0% (min. 
90.5%, max. 98.6%) and a properly paired rate of 72.0% (min. 67.6%, max. 74.2%). The 
cornea tissues had an average alignment rate of 96.5% (min. 89.2%, max. 98.4%) and a 
properly paired rate of 71.6% (min 69.8%, max. 73.0%). The CB tissues had an average 
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alignment rate of 97.3% (min. 96.6%, max. 98.0%) and a properly paired rate of 74.3% 
(min 69.9%, max. 74.4%). 
The resulting alignment files were merged based on tissue and age (6 
transcriptomes total: adult and fetal TM, cornea, and CB). Pooling samples improves 
overall read depth, resulting in more accurate isoform expression estimates. The 
transcriptomes were assembled using the Cufflinks program in two different ways 
(Trapnell, Williams et al. 2010). For both, a reference transcriptome was supplied. The 
first (assembly 1) did not allow for the identification of novel transcripts (-G) and only 
called transcripts previously annotated in the human transcriptome reference file 
supplied by Ensembl (build GRCH37). The second (assembly 2) allowed for the 
identification of novel transcripts, but used the known transcriptome as a guide (--GTF-
guide). The goal of assembly 1 is to accurately estimate gene expression levels. The goal 
of assembly 2 is to identify novel isoforms of candidate genes. The Cufflinks program 
was run using the default parameters modified to allow for an increased number of 
reads per locus (--max-bundle-frags) and a larger genomic length per bundle (--max-
bundle-length).  
Post assembly, output files were annotated using Ensembl build GRCH37 
annotation files. Genes with the GENCODE biotype (http://www.gencodegenes.org/ 
gencode_biotypes.html) of Mt_rRNA, Mt_tRNA, Mt_tRNA_pseudogene, rRNA, 
rRNA_pseudogene, or tRNA pseudogene, and deprecated genes (predicted protein 
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coding or non-coding RNAs from previous version of the human genome reference that 
have been removed from the current version) were removed from the descriptive 
analysis. Genes that failed the analysis (given in the Cufflinks output files as ‘lowdata’ 
and ‘failed’) were also removed. A gene or transcript was determined to be expressed if 
the fragments per kilobase of transcript per million mapped reads (FPKM) were equal to 
or great than 1. Downstream descriptive analyses were performed in SAS (SAS Institute 
Inc. 2002-2008). Post assembly transcriptome files were viewed in RNAseqViewer (Roge 
and Zhang 2013). 
  
4.3 Results 
4.3.1 Ocular tissue sample characteristics 
Sixteen ocular tissues samples were selected from a collection of tissues available through the North Carolina 
Eye Bank. Sample characteristics are shown in Table 8. 
Table 8: Ocular tissue sample characteristics 
Sample Age Race Sex 
Post 
Mortem  
Delay 
Cause of 
Death 
Tissue 
1 28 week gestation Caucasian M 4:40 Prematurity TM, Cornea, CB 
2 23 week gestation Caucasian F 13:28 Prematurity TM, Cornea 
3 73 Caucasian M 6:46 Sepsis TM, Cornea, CB 
4 76 Caucasian F 4:14 Myocardial infarction TM, Cornea, CB 
5 66 Caucasian M 3:56 
Small bowel 
obstruction 
TM, Cornea 
6 66 Caucasian F 4:00 Sepsis TM, Cornea, CB 
7
3 
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4.3.2 Characteristics of the trabecular meshwork, cornea, and ciliary 
body transcriptomes 
4.3.2.1 Initial filtering and annotation 
Utilizing the output from assembly 1 (requiring transcripts to match the 
annotated human transcriptome), the total number of expressed genes was evaluated. 
Gene expression output is given in fragments per kilobase of transcript per million 
mapped reads (FPKM), a measure of gene expression normalized by gene length and 
reads/sample. Before any filters were applied, the average number of genes with an 
FPKM value > 0 expressed in each tissue ranged from 27,523 to 36,685. To improve 
confidence in the downstream analyses, an FPKM threshold of 1, generally accepted to 
be above background noise, was used. After applying this filter, the average number of 
genes expressed in each tissue ranged from 12,628 to 16,684 (Appendix G). The 
expression value of several genes (an average of 57/sample) could not be determined by 
the calling algorithm (flagged as failed and low data), and these were removed. Next, 
genes were annotated based on the GENCODE biotype provided with the Ensembl 
reference annotation files (Appendix H). Genes with the following biotypes were 
removed: Mt_rRNA, Mt_tRNA, Mt_tRNA_pseudogene, rRNA, rRNA_pseudogene, and 
tRNA_pseudogene. Looking at the distribution and top most expressed genes before 
additional filters were applied revealed that the gene expression distribution is heavily 
skewed (Appendix I) and that there is an overrepresentation of deprecated genes in the 
top most expressed genes (Appendix J). These were excluded from the final analysis, 
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although this does not ensure other deprecated or undefined genes do not remain in the 
dataset due to complications in genome annotation. 
4.3.2.2 Distribution of gene expression in six ocular tissue RNA-seq datasets 
After the initial filter, the number of genes expressed was determined by looking 
at the FPKM values. An average of 15,099 genes were expressed in each tissue (Table 9). 
The distribution is heavily skewed; interquartile ranges are provided in Table 9. The 
adult CB sample had the smallest number of expressed genes (N = 12,101), but the 
highest gene expression value (FPKM = 40,456). The adult TM had the largest number of 
expressed genes (N = 17,175). 
Table 9: Distribution of gene expression values in six ocular tissue RNA-seq 
datasets 
Sample N Q1-25% Median Q3-75% FPKM Max 
Adult TM 17,175 3.39 8.98 21.99 23,949 
Fetal TM 15,980 3.28 8.22 20.00 21,479 
Adult Cornea 15,934 3.29 9.11 23.76 15,484 
Fetal Cornea 16,157 3.33 8.49 20.13 13,533 
Adult CB 12,101 2.66 8.15 30.70 40,456 
Fetal CB 13,247 2.52 7.34 27.92 7,438 
Average 15,099 3.08 8.38 24.08 20,390 
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4.3.3 Most highly expressed genes in adult and fetal trabecular 
meshwork, cornea, and ciliary body tissues 
The most highly expressed genes per tissue type were determined by ranking the 
calculated gene expression level by the FPKM. Table 10 shows the top ten most 
expressed genes in the overall dataset. Most tissues showed high gene expression levels 
for mitochondrial genes, particularly mitochondrially encoded ATP synthases, 
mitochondrially encoded cytochrome c oxidases, and mitochondrially encoded NADH 
dehydrogenases. Excluding these, the top twenty most expressed genes in each tissue 
are given in Tables 11-16. 
Table 10: Top ten most expressed genes overall from trabecular meshwork, cornea, 
and ciliary body ocular tissue samples 
Sample Ensemble ID Locus Gene Name FPKM 
Adult 
CB 
ENSG00000228253 MT:8365-8572 MT-ATP8 40,456 
Adult 
TM 
ENSG00000228253 MT:8365-8572 MT-ATP8 23,949 
Adult 
CB 
ENSG00000107317 9:139871955-139879887 PTGDS 22,151 
Fetal 
TM 
ENSG00000113140 5:151040656-151066726 SPARC 21,479 
Adult 
CB 
ENSG00000198899 MT:8526-9207 MT-ATP6 15,848 
Adult 
Cornea 
ENSG00000228253 MT:8365-8572 MT-ATP8 15,484 
Fetal 
TM 
ENSG00000108821 17:48260649-48278993 COL1A1 14,647 
Adult 
Cornea 
ENSG00000226958 X:108297360-108297792 CTD-2328D6.1 13,931 
Fetal 
Cornea 
ENSG00000113140 5:151040656-151066726 SPARC 13,533 
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Table 11: Top twenty most expressed genes from adult trabecular meshwork 
Adult Trabecular Meshwork 
Gene ID Gene Name FPKM 
RNU1-4 RNA, U1 small nuclear 4 10,704 
RNU1-2 RNA, U1 small nuclear 2 10,678 
APOD apolipoprotein D 10,052 
B2M beta-2-microglobulin 5,198 
RNY4 RNA, Ro-associated Y14 4,570 
RNY1 RNA, Ro-associated Y1 4,383 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 3,962 
PTGDS prostaglandin D2 synthase 21kDa (brain) 3,912 
ANGPTL7 angiopoietin-like 7 3,693 
RNU1-5 RNA, variant U1 small nuclear 18 3,630 
RNU1-6 RNA, variant U1 small nuclear 9 3,622 
RNU1-9 RNA, variant U1 small nuclear 7 3,622 
RNU1-3 RNA, U1 small nuclear 3 3,603 
RNU1-1 RNA, U1 small nuclear 1 3,596 
RNU1-7 RNA, U1 small nuclear 27, pseudogene 3,570 
RNU1-8 RNA, U1 small nuclear 28, pseudogene 3,569 
TPT1 tumor protein, translationally-controlled 1 3,183 
S100A9 S100 calcium binding protein A9 3,169 
CLU clusterin 2,991 
TMSB4X thymosin beta 4, X-linked 2,441 
Of the top twenty most highly expressed genes in the adult trabecular 
meshwork, 12 were mitochondrial encoded proteins (not shown). Pseudogenes and 
ribosomal proteins are not shown. 
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Table 12: Top twenty most expressed genes from fetal trabecucular meshwork 
Fetal Trabecular Meshwork 
Gene ID Gene Name FPKM 
Name 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 21,479 
COL1A1 collagen, type I, alpha 1 14,648 
COL1A2 collagen, type I, alpha 2 10,909 
ANGPTL7 angiopoietin-like 7 5,962 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 5,309 
TPT1 tumor protein, translationally-controlled 1 2,730 
MGP matrix Gla protein 2,609 
DCN decorin 2,324 
FMOD fibromodulin 2,213 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa 1,774 
PCOLCE procollagen C-endopeptidase enhancer 1,743 
EEF1A1P5 eukaryotic translation elongation factor 1 alpha 1 
pseudogene 5 
1,364 
FTL ferritin, light polypeptide 1,295 
COL3A1 collagen, type III, alpha 1 1,278 
BGN biglycan 1,263 
GNB2L1 guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1 
1,182 
ELN elastin 1,162 
TMSB4X thymosin beta 4, X-linked 1,160 
NACA nascent polypeptide-associated complex alpha subunit 1,116 
MYL6 myosin, light chain 6, alkali, muscle and non-muscle 1,107 
Of the top twenty most highly expressed genes in the fetal trabecular meshwork, 
9 were mitochondrial encoded proteins (not shown). Pseudogenes and ribosomal 
proteins are not shown. 
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Table 13: Top twenty most expressed genes from adult cornea 
Adult Cornea 
Gene ID Gene Name FPKM 
CLU clusterin 12,074 
KRT5 keratin 5 8,213 
FTH1 ferritin, heavy polypeptide 1 6,377 
KRT12 keratin 12 5,838 
S100A4 S100 calcium binding protein A4 5,829 
S100A9 S100 calcium binding protein A9 4,644 
S100A6 S100 calcium binding protein A6 4,570 
TMSB4X thymosin beta 4, X-linked 4,111 
B2M beta-2-microglobulin 3,789 
TGFBI transforming growth factor, beta-induced, 68kDa 3,268 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 3,141 
ENO1 enolase 1, (alpha) 3,129 
TPT1 tumor protein, translationally-controlled 1 3,083 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 2,981 
S100A8 S100 calcium binding protein A8 2,835 
MT1X metallothionein 1X 2,737 
KRT13 keratin 13 2,465 
HSPB1 heat shock 27kDa protein 1 2,432 
KRT14 keratin 14 2,242 
GSTP1 glutathione S-transferase pi 1 1,939 
Of the top twenty most highly expressed genes in the adult cornea, 10 were 
mitochondrial encoded proteins (not shown). Pseudogenes and ribosomal proteins are 
not shown. 
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Table 14: Top twenty most expressed genes from fetal cornea 
Fetal Cornea 
Gene ID Gene Name FPKM 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 13,533 
COL1A1 collagen, type I, alpha 1 11,759 
COL1A2 collagen, type I, alpha 2 11,582 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 5,123 
DCN decorin 5,026 
LUM lumican 4,413 
KERA keratocan 3,448 
KRT5 keratin 5 3,122 
H19 H19, imprinted maternally expressed transcript 2,522 
FMOD fibromodulin 2,481 
TPT1 tumor protein, translationally-controlled 1 2,196 
KRT12 keratin 12 2,181 
COL5A1 collagen, type V, alpha 1 2,176 
TMSB4X thymosin beta 4, X-linked 1,873 
MGP matrix Gla protein 1,591 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 1,575 
COL5A2 collagen, type V, alpha 2 1,442 
EEF1A1P5 Euk. translation elongation factor 1 alpha 1 pseudogene 5 1,364 
COL6A1 collagen, type VI, alpha 1 1,273 
CLU clusterin 1,235 
Of the top twenty most highly expressed genes in the fetal cornea, 8 were 
mitochondrial encoded proteins (not shown). Pseudogenes and ribosomal proteins are 
not shown. 
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Table 15: Top twenty most expressed genes from adult ciliary body 
Adult Ciliary Body 
Gene ID Gene Name FPKM 
PTGDS prostaglandin D2 22,151 
GPX3 glutathione peroxidase 3 (plasma) 7,507 
FTH1 ferritin, heavy polypeptide 1 6,339 
IFITM3 interferon induced transmembrane protein 3 4,500 
ALDOA aldolase A, fructose-bisphosphate 3,488 
OPTC opticin 3,169 
TRAJ49 T cell receptor alpha joining 49 2,769 
EEF2 eukaryotic translation elongation factor 2 2,733 
MYH11 myosin, heavy chain 11, smooth muscle 2,359 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 2,097 
PKM2 pyruvate kinase, muscle 2,072 
SERPING1 serpin peptidase inhibitor, clade G, member 1 2,005 
MYL9 myosin, light chain 9, regulatory 1,933 
AES amino-terminal enhancer of split 1,887 
CKB creatine kinase, brain 1,887 
CRYAB crystallin, alpha B 1,873 
IGHJ5 immunoglobulin heavy joining 5 1,733 
FTL ferritin, light polypeptide 1,563 
GSN gelsolin 1,550 
APOD apolipoprotein D 1,541 
Of the top twenty most highly expressed genes in the adult ciliary body, 12 were 
mitochondrial encoded proteins (not shown). Pseudogenes and ribosomal proteins are 
not shown. 
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Table 16: Top twenty most expressed genes from fetal ciliary body 
Fetal Ciliary Body 
Gene ID Gene Name FPKM 
PTGDS prostaglandin D2 synthase 21kDa (brain) 6,800 
CLU clusterin 4,954 
FTH1 ferritin, heavy polypeptide 1 4,232 
EEF2 eukaryotic translation elongation factor 2 4,141 
H19 H19, imprinted maternally expressed transcript 3,583 
ELN elastin 3,398 
COL9A2 collagen, type IX, alpha 2 2,620 
VIM vimentin 2,511 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 2,257 
GNAS GNAS complex locus 2,049 
COL9A3 collagen, type IX, alpha 3 1,991 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 1,974 
PMEL premelanosome protein 1,780 
ALDOA aldolase A, fructose-bisphosphate 1,616 
BSG basigin (Ok blood group) 1,533 
ACTB actin, beta 1,512 
COL6A2 collagen, type VI, alpha 2 1,507 
ACTG1 actin, gamma 1 1,479 
DES desmin 1,456 
COL6A1 collagen, type VI, alpha 1 1,441 
Of the top twenty most highly expressed genes in the fetal ciliary body, 6 were 
mitochondrial encoded proteins (not shown). Pseudogenes and ribosomal proteins are 
not shown. 
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4.3.4 Gene expression of POAG GWAS candidate genes and 
identification of novel isoforms 
The gene expression levels of ten well-established POAG candidate genes, 
identified by genome-wide association studies, were determined for each tissue type 
(Table 17) (Janssen, Gorgels et al. 2013). Based on the overall gene expression 
distribution, genes with an FPKM > 1, an FPKM > 4.3 (33rd percentile), and an FPKM > 
16.3 (67th percentile) were determined to be lowly (highlighted in yellow), moderately 
(highlighted orange), or highly expressed (highlighted red), respectively.  
Table 17: Gene expression of POAG candidate genes 
GENE 
Adult 
TM 
Fetal 
TM 
Adult 
Cornea 
Fetal 
Cornea 
Adult 
CB 
Fetal 
CB 
ATOH7 0.06 1.21 0.14 0.29 0.03 0.52 
CAV1 34.44 35.47 25.13 43.07 0.87 0.41 
CAV2 32.57 14.05 27.43 14.86 2.45 1.67 
CDKN2A 3.87 0.02 10.86 0.44 0.58 0.11 
CDKN2B 14.66 0.05 27.19 4.32 0.11 0.10 
CDKN2B-AS 0.67 0.10 0.67 0.07 0.02 0.00 
ELOVL5 49.05 29.79 14.50 19.63 1.28 0.87 
SIX6 0.02 0.96 0.01 1.95 13.77 18.22 
SRBD1 4.53 4.51 4.41 5.97 0.10 0.18 
TMCO1 54.34 45.51 66.41 56.79 1.42 0.65 
 
Of the genes investigated, most showed some evidence of expression. The 
CDKN2B, CDKN2A, and CDKN2B-AS genes represent a highly replicated POAG-
associated locus, although currently the causal gene(s) remains unknown. Interestingly, 
CDKN2B-AS was not found to be expressed in any of the tissues studied, suggesting 
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CDKN2B and CDKN2A may be better candidate genes for follow-up studies. SIX6, 
which is generally considered to function in posterior structures of the eye during 
development, was found to be highly expressed in the human adult and fetal ciliary 
body.  
We also looked for the presence of novel isoforms in the POAG candidate gene 
loci. Using a FPKM cutoff of 1, three loci (CDKN2B, SIX6, and SRBD1) contained five 
potentially novel isoforms. The remaining loci (ATOH, CAV1/CAV2, ELOVL5, TMCO1) 
contained evidence of novel isoforms (FPKM > 0), but these isoforms had expression 
values below the set threshold (FPKM < 1), reducing confidence in their existence (Table 
18).  
 
Table 18: Evidence of novel isoforms in POAG candidate genes 
All seven of the loci investigated contained evidence of novel isoform expression. Four 
of these loci had FPKM values below the threshold (designated by an FPKM < 1 in the 
novel isoforms column). Five novel isoforms above the FPKM threshold were identified. 
Locus Coordinates Novel Isoforms Sample 
ATOH7 10:69988385-69993871 FPKM < 1 -- 
CAV1/CAV2 7:115925433-116203233 FPKM < 1 -- 
CDKN2B 9:21965750-22123096 2 Novel Adult TM, Adult Cornea 
ELOVL5 6:53130195-53215947 FPKM < 1 -- 
SIX6 14:60973668-60981568 1 Novel Fetal CB 
SRBD1 2:45613818-45841304 2 Novel Adult TM, Adult CB 
TMCO1 1:165694031-165740417 FPKM < 1 -- 
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Four novel isoforms with FPKM values > 1 were identified at the CDKN2B and 
SRBD1 loci in the adult TM, CB, and cornea tissues. SIX6, which showed high expression 
in the ciliary body, contained a potentially novel isoform in the fetal ciliary body tissue 
(Table 19). The two most expressed novel isoforms were identified in two genes highly 
associated with POAG in the NEIGHBOR/GLAUGEN meta-analysis (CDKN2B and 
SIX6). The novel isoforms at the CDKN2B locus were similar to the transcript 
ENST00000276925, with modified end points (Figure 10). However, the novel SIX6 
isoform is significantly different from any known transcript (Figure 11). 
 
Table 19: Expression of novel isoforms at the CDKN2B, SIX6 and SRBD1 loci 
Sample Locus Transcript Coordinates FPKM 
Adult TM CDKN2B 9:22002954-22009337 3.31 
Adult Cornea CDKN2B 9:22002901-22009371 4.44 
Fetal CB SIX6 14:60975411-60978231 32.06 
Adult TM SRBD1 2:45615913-45776211 1.31 
Adult CB SRBD1 2:45673652-45673918 1.65 
  
 
Figure 10: Novel isoforms at the CDKN2B locus identified in human adult trabecular meshwork and cornea 
samples 
Potentially novel isoforms are shown in light blue and are assigned a unique identifier by the Cufflinks program 
(CUFF.xxx). Two novel isoforms at the CDKN2B locus were identified in the adult TM and cornea. The closest related 
isoforms from the human genome references, Hg19 and GRCH37, are shown above. 
 
 
Figure 11: Novel isofrom at the SIX6 locus identified in the fetal ciliary body sample 
A potentially novel isoform at the SIX6 locus identified in the fetal CB sample (bottom) and the most closely related 
isoforms from the human genome references, Hg19 and GRCH37, are shown above. 
8
6 
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4.4 Discussion 
RNA sequencing (RNA-seq) is an enormously informative approach for 
transcriptome analysis and does not rely entirely on a priori knowledge (Wang, Gerstein 
et al. 2009). It has been used extensively to study healthy and diseased human tissues. 
However, ocular tissues, especially anteriorly located tissues like the trabecular 
meshwork, cornea, and ciliary body, have not previously been interrogated with this 
approach. These tissues are essential for normal ocular function and play important 
roles in common diseases like glaucoma. In this study, the transcriptional landscape of 
the trabecular meshwork, cornea, and ciliary body was described using RNA-seq, and 
the resulting data will be directly applicable in the future for a wide range of ocular 
research fields. 
 On average, we identified over 15,000 expressed genes in each tissue. This is 
consistent with the findings of a recent study that used a similar approach for analyzing 
the human limbus, a tissue that connects the cornea and the sclera (Bath, Muttuvelu et 
al. 2013) . While descriptive statistics, such as the number of expressed genes and the 
distribution of gene expression levels, provide essential tissue specific insight into the 
transcriptome, the data generated in this study may be used in a variety of additional 
ways to propel ocular research forward. As we have shown, it can be used to explore the 
expression of candidate genes in disease relevant tissues, which can help with the 
prioritization of candidate genes identified in association studies. Genetic association 
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studies can identify novel regions of interest, but are limited in their ability to directly 
identify causal genes due to the high correlation that is often locally observed at genetic 
loci. Using RNA-seq data to identify expression in relevant tissues helps narrow the 
search. We used this approach and showed CDKN2A and CKDN2B are highly expressed 
in POAG-related tissues, while CDKN2B-AS was not found to be expressed in any of the 
tissues examined. This locus is associated with POAG, but the exact causal gene(s) 
remains unknown (Burdon, Macgregor et al. 2011; Osman, Low et al. 2012; Wiggs, 
Yaspan et al. 2012; Janssen, Gorgels et al. 2013). The RNA-seq data suggest CDKN2A and 
CKDN2B could be given priority over CDKN2B-AS in future POAG functional analyses. 
This, of course, is not conclusive; CDKN2B-AS may function in other relevant tissues, 
like the retina and optic nerve, or may be expressed in diseased tissues. But, the RNA-
seq data has provided a starting point for functional follow-up and aided in hypothesis 
generation. 
In addition to evidence of candidate gene expression, RNA-seq data can be used 
to investigate transcript level information. The specific isoforms of a protein may vary 
by tissue and identifying specific transcript expression can help with the design of 
functional follow-up studies. This can be enhanced by using an analytical approach, like 
the one presented in this study, which allows for the identification of completely novel 
transcripts. The tissues included in this study were predominately selected based on 
their relevance to glaucoma biology. So, we specifically looked at transcript level 
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expression of candidate genes identified via POAG genome-wide association studies. 
We identified several potentially novel isoforms in POAG candidate genes including the 
SIX6 gene. This gene is of particular interest due to the recent identification of POAG 
specific, functional alleles (Chapter 3). Interestingly, SIX6 was found to be highly 
expressed in the adult and fetal ciliary body. While Aijaz et al. previously showed the 
presence of SIX6 expression in the human ciliary body, this gene is primarily considered 
a retinal specific development gene (Kawakami, Sato et al. 2000; Aijaz, Allen et al. 2005; 
Kumar 2009). We identified a novel SIX6 transcript in the fetal ciliary body that is 
remarkably different than any currently known. While this could be an artifact of the 
program’s calling algorithm due to the complicated nature of the sequencing data, it is 
possible SIX6 has a novel function in ciliary body development and POAG susceptibility 
that remains unknown. More work is needed to confirm the presence of novel isoforms 
in these tissues and determine what role they may have in ocular function. 
 While RNA-seq is undoubtedly useful, there are some limitations that can 
hamper downstream applications. In theory, high-throughput sequencing of the entire 
mRNA population within a cell or tissue eliminates the need for a complete, annotated 
transcriptome. This is especially important in less studied tissues, like those included in 
this analysis, because the transcriptome can be highly tissue specific. However, 
interpretability without the annotation can very difficult. In our dataset, we identified 
highly expressed genes that are currently labeled as deprecated genes, meaning they 
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were once considered possible transcripts in previous versions of the reference 
transcriptome, but have now been removed. The current annotation makes it difficult to 
infer what role these genes may play in the biology of these tissues. This highlights the 
need for functional validation, which will become increasingly important as this 
technique is more frequently applied. 
The overall goal of this study was to increase our understanding of the 
transcriptional landscape of POAG-related tissues and to generate a dataset that could 
help guide future research. We have shown the benefits of an RNA-seq approach by the 
identification of potentially novel isoforms and, by looking at a selection of POAG 
candidate genes, several novel hypotheses have emerged. This approach could be 
extended to other ocular diseases involving the trabecular meshwork, cornea, and ciliary 
body, and is therefore broadly applicable to many areas of ocular research.  
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5. Conclusion 
5.1 Project specific considerations and future directions 
Primary open-angle glaucoma (POAG) is a common blinding disease with a 
complex genetic component. The overall goal of studying the genetics of POAG is to 
better understand who may be at an increased risk of developing the disease 
(prediction) and the underlying biological mechanisms (biology) in order to better treat 
patients in the future. The work presented in Chapters 2-4 directly contribute to the field 
in different ways: Chapter 2) increasing the knowledge-base of a commonly studied 
POAG quantitative risk factor (prediction); Chapter 3) the characterization of a POAG 
candidate gene and the identification of functional variants from a genetically associated 
locus (prediction and biology); and Chapter 4) a description of the transcriptional 
landscape of essential POAG-related tissues (biology). 
5.1.1 POAG endophenotype analyses 
As described in Chapter 2 (Central corneal thickness (CCT) analysis: a potential 
POAG endophenotype), the identification of disease susceptibility alleles via 
quantitative endophenotypes is an attractive approach. An endophenotype is defined 
here as a heritable quantitative trait that is state independent (present within the normal 
population), associated with a disease, and is assumed to lie within the causal pathway 
(Flint and Munafo 2007; Kendler and Neale 2010). Endophenotypes are of particular 
importance in diseases like POAG because often the endophenotype is easier to measure 
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than the disease itself. If a trait is a true endophenotype, there may be SNPs that directly 
affect the quantitative trait (e.g. reduction in CCT) which may then lead to or increase 
susceptibility to the disease. If this is the case, the causal SNP(s) would be associated 
with both traits (the endophenotype and the disease).  
Often, studies of potential endophenotypes are conducted as secondary trait 
analyses, where a genome-wide dataset is re-analyzed for the secondary trait of interest. 
While secondary trait analyses are appealing because they are cost effective and can 
provide a unique dataset (e.g. CCT analysis in the context of POAG cases), they can also 
be greatly affected by biases. This is especially true when the secondary trait is 
associated with the primary trait, which can lead to an inflated Type I error rate 
(Monsees, Tamimi et al. 2009; Kendler and Neale 2010). Of course the level of the Type I 
error is dependent on the effect of the associated endophenotypes and SNP(s) (i.e. if the 
secondary trait has only a marginal effect on the disease, the bias will be small). An 
example of this issue is observed in genetic studies of intraocular pressure (van 
Koolwijk, Ramdas et al. 2012; Ozel, Moroi et al. 2014). Using the NEIGHBOR and 
GLAUGEN POAG case-control dataset, we identified SNPs in GAS7 and TMCO1, 
known to be associated with POAG, which were also significantly associated with 
intraocular pressure (Ozel, Moroi et al. 2014). Because the distribution of intraocular 
pressure is significantly different in POAG cases compared to controls, any SNPs 
associated with POAG are going to consequentially appear to be associated with 
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differences in intraocular pressure, making it difficult to postulate if the original 
hypothesis is correct (causal SNP directly increases intraocular pressure which then 
directly increases POAG risk).  
So, how does one determine if the observed association signal from a secondary 
analysis is due to study design bias or a true endophenotype status? While there is no 
clear answer, certain approaches can be used to help clarify the true relationship. 
Population-based data are less likely, depending on the disease prevalence, to be 
susceptible to these biases. In other words, if a SNP is associated with the secondary trait 
in a population-based cohort, it is less likely to be due to allele frequency differences 
caused by an underlying association to a disease. This increases the confidence that the 
SNP may directly affect the tested trait. Looking for an overlap of genetic associations 
from population-based studies provides increased evidence that a trait may be a true 
endophenotype. This is the case with the association of intraocular pressure and the 
GAS7 and TMCO1 genes and the association of vertical cup-disc ratio and the SIX6 gene, 
discussed in Chapter 3. In both cases, the genetic associations of the quantitative risk 
factors were observed in non-diseased populations and independently shown to 
increase disease risk in POAG case-control datasets, suggesting intraocular pressure and 
vertical cup-disc ratio may be true POAG endophenotypes (Charlesworth, Kramer et al. 
2010; Macgregor, Hewitt et al. 2010; Ramdas, van Koolwijk et al. 2010; van Koolwijk, 
Ramdas et al. 2012; Wiggs, Yaspan et al. 2012; Ozel, Moroi et al. 2014). This, however, 
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was not observed in central corneal thickness analyses, and there is mounting evidence 
suggesting CCT may not be a true POAG endophenotype (discussed more in Chapter 2) 
(Charlesworth, Kramer et al. 2010; Dimasi, Burdon et al. 2012).  
These studies, which focus on identifying the shared genetics of an 
endophenotype and a trait, are unable to decipher between pleiotropy, where SNP(s) 
cause both the quantitative trait and the disease, and mediation, where the quantitative 
risk factor lies within the causal pathway. Mediation analyses may help decipher 
between the two in some circumstances. This analytical approach directly tests the 
hypothesis of pleiotropy versus mediation using statistical methods (MacKinnon, 
Lockwood et al. 2002; Kendler and Neale 2010). However, to fully understand the 
relationship between SNPs associated with quantitative risk factors and the disease of 
interest, functional laboratory-based assays are ultimately needed. An example of this is 
discussed in Chapter 3 (Discovery and functional annotation of SIX6 variants in POAG), 
where we showed that the SIX6 locus, associated with both vertical cup-disc ratio and 
POAG, likely functions via quantitative changes to the retina.  
Finally, elucidating the exact endophenotypic status of quantitative risk factors 
may not be essential if the overall goal is disease prediction. Instead, building prediction 
models that account for both the genetic and quantitative trait effects and that can 
accurately assess the potential for disease development would result in earlier disease 
diagnosis. Individuals could then be preemptively treated with intraocular pressure 
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reducing topical medications, which have been shown to be effective in slowing POAG 
progression even in the absence of ocular hypertension (Collaborative Normal-Tension 
Glaucoma Study Group 1998; Heijl, Leske et al. 2002; Miglior, Pfeiffer et al. 2007). In 
combination with continued basic research, an emphasis on developing clinically 
accessible predictive models could have an enormous impact on improving the rate of 
blindness caused by glaucoma. A predictive model for POAG was published 2007 
(Gordon, Torri et al. 2007). However, this model does not account for newly discovered 
genetic markers, may not be applicable to individuals under the age of 40, and is limited 
to ocular hypertensives, which represent only a subset of POAG cases (Dielemans, 
Vingerling et al. 1994; Iwase, Suzuki et al. 2004; Varma, Ying-Lai et al. 2004; Coleman 
and Miglior 2008; Mudumbai 2013).  
One of the additional challenges with predictive modeling is that many of the 
well-established quantitative POAG risk factors are not routinely measured in 
undiagnosed individuals. Therefore, for predictive modeling to be successful, known 
quantitative risk factors like central corneal thickness and vertical cup-disc ratio need to 
be more commonly measured. Predictive modeling could dramatically improve the 
prognosis for POAG patients. There is much room for growth in this area, and it should 
be considered a priority by POAG researchers in the future. 
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5.1.2 The role of SIX6 in POAG 
The study of the discovery and functional annotation of SIX6 variants in POAG 
(Chapter 3) is the first true functional follow-up to a POAG genome-wide association 
study. It is unique in the fact that the alleles tested were directly identified in POAG 
cases and showed that rare and common variants influence the protein’s functionality. 
Interestingly, SIX6 is traditionally thought of as a developmental gene, while POAG has 
a late age of onset. This study revealed that developmental processes, retinal ganglion 
cells development in this case, may affect POAG onset decades later. There is still much 
to learn about this gene and its role in POAG. 
Understanding more about the normal functional of the SIX6 gene could teach us 
about the biology of POAG and may result in the identification of additional candidate 
genes or pathways. This can be challenging since SIX6 has a restricted range of gene 
expression (primarily expressed in posterior ocular tissues and the pituitary). To learn 
more about the gene’s basic function, pituitary cell lines may be of use since they are 
easily available, well-established, and should endogenously express the SIX6 gene. SIX6 
is a known transcription factor, but a comprehensive characterization of its downstream 
targets has not been completed. An appropriate approach would be to perform 
chromatin immunoprecipitation-sequencing (ChIP-seq) using anti-bodies targeting SIX6 
in a pituitary cell line. While this approach does not directly answer questions related to 
the role of SIX6 in POAG, it does provide a wealth of novel information which could be 
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used to direct future POAG studies. Immediate downstream targets of SIX6 could be 
considered as high priority candidate genes because they may also function to increase 
POAG susceptibly. This could be tested using a genetic association analysis or 
performing a zebrafish morpholino assay, similar to approach described in Chapter 3. In 
addition, understanding intricate gene networks is useful in complex disease research as 
downstream targets of any POAG causal gene could be considered as potential targets 
for drug therapy. 
An experiment looking at the gene expression or protein level changes of a 
retinal ganglion cell biomarker (POU4F2) in morpholino or cell culture-based 
knockdown assays would be a more direct approach for studying the role of SIX6 in 
POAG and for testing our primary hypothesis (SIX6 regulates the number of retinal 
ganglion cells created during development). The POU4F2 gene is expressed almost 
exclusively in retinal ganglion cells, and therefore can be used to extrapolate the total 
number of retinal ganglion cells present (Xiang, Zhou et al. 1993). Correlating changes in 
POU4F2 after knockdown, rescue, and co-injection of POAG specific alleles would 
provide further evidence that SIX6 increases POAG susceptibility via a direct effect on 
retinal ganglion cell development. In a similar manner, other potential candidate genes 
could be analyzed. Cell cycle control genes are of particular interest. There are several 
lines of evidence that suggest members of the SIX gene family directly bind and regulate 
the expression of cyclin-dependent kinase inhibitor (CDKN) genes (Li, Perissi et al. 2002; 
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Del Bene and Wittbrodt 2005; Iglesias, Springelkamp et al. 2013). Interestingly, a locus at 
Chr.9p21, that houses CDKN2A, CDKN2B, and CDKN2B-AS1, is highly associated with 
POAG (Gibson, Griffiths et al. 2012; Osman, Low et al. 2012; Wiggs, Yaspan et al. 2012; 
Janssen, Gorgels et al. 2013). The interaction of these two loci would be a novel finding 
with major implications in the field of POAG research. 
In Chapter 3, we showed that coding and regulatory variants at the SIX6 locus 
had a functional effect. We hypothesized regulatory variants may influence the level of 
SIX6 gene expression, which could in turn influence POAG susceptibility. We focused 
our efforts on a small region upstream of the SIX6 gene containing a well-defined 
enhancer element. The current study could be expanded by extending our approach to 
include the SIX6 promoter region. Because the promoter has not been defined, a 
promoter bashing experiment should be performed first to define the region. Then, 
repeating the experiments presented in Chapter 3, POAG cases and controls should be 
sequenced, constructs containing disease alleles generated, and a luciferase assay should 
be used to test the effects of the identified variants. The enhancer variants previously 
identified were extraordinarily rare and, due to the small sample size used in our 
sequence study, we were unable to perform association testing at this region. Therefore, 
this experiment could also be extended by sequencing additional individuals and 
performing a rare variant association test to determine if the presences of rare regulatory 
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variants are more common in POAG cases than controls, providing further evidence the 
regulatory region may play a causal role in disease development.  
5.1.3 The transcriptional landscape of POAG-related tissues 
One goal of the work described in Chapter 4 (The transcriptional landscape of 
POAG-related tissues: the trabecular meshwork, cornea, and ciliary body) was to learn 
about the basic biology of essential ocular tissues. This was completed by the descriptive 
analysis of the transcriptome of each tissue at two different developmental stages (fetal 
and adult). There are many follow-up analyses that can be conducted with the RNA-seq 
data generated during this project. Of particular interest, a differential gene expression 
analysis comparing the developmental stages could be performed. A related study was 
recently published (Young, Hawthorne et al. 2013). In this study, global gene expression 
profiles from fetal and adult ocular tissues (retina, choroid, sclera, optic nerve, and 
cornea) were compared. As described by Young et al., comparing gene expression 
profiles at these two time points aids in the identification of genes involved in normal 
ocular development as well as genes potentially responsible for diseases characterized 
by ocular growth abnormalities, such as myopia. The RNA-seq data generated in 
Chapter 4 could be analyzed using a similar approach. This analysis differs from the 
previous study in two important ways: 1) our dataset contains two unique tissues types 
(trabecular meshwork and ciliary body) and 2) our study was conducted with RNA-seq 
rather than a microarray-based platform. Because of these differences, our analysis could 
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yield novel results that may not have been identified in the original study. Additionally, 
this analysis could serve to replicate the original findings and improve the overall 
confidence in the results. 
Using the RNA-seq data, we showed that many POAG candidate genes are 
expressed in relevant tissues. We also showed that an important POAG candidate gene 
(CDKN2B-AS) was not expressed in the tissues examined. Finally, we identified several 
novel isoforms. This analysis could easily be extended to include additional POAG 
candidate genes or to include genes from additional phenotypes such as POAG-related 
quantitative traits. The same approach, determining the level of gene expression and 
looking for evidence of novel isoforms, could be applied to these additional candidate 
genes. Genes identified in central corneal thickness studies, discussed in Chapter 2, 
would be particularly interesting candidates for follow-up analyses. Similarly, it would 
be valuable to look at the trabecular meshwork and ciliary body RNA-seq data for genes 
previously associated with intraocular pressure because of the known role these tissues 
have in intraocular pressure regulation.  
 While the identification of novel isoforms in POAG candidate genes is intriguing, 
these need to be validated. Any inferences made from the RNA-seq data could be 
incorrect due to random error, errors caused by flaws in the program’s calling 
algorithm, or individual variability. Therefore, validation of the results is essential. 
Unfortunately, the fetal ocular tissues were extremely small and were consumed during 
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the RNA sequencing process. Therefore, the first step for validation is to collect 
additional ocular samples and extract RNA. To confirm the presence of the novel 
isoforms identified, a combination of real-time PCR and 5 prime or 3 prime RACE (rapid 
amplification of cDNA ends) will need to be conducted in the proper tissues types 
(Sambrook and Russell 2006). Additionally, any differentially expressed genes identified 
in a fetal versus adult comparative study will need to be validated using a real-time PCR 
or a similar approach in order to ensure the accuracy of the results. 
The ultimate goal is to propel the field forward with the biology learned from the 
RNA-seq analysis. This dataset is broadly applicable to a wide range of ocular studies, 
so it should be shared with the research community. One possibility is to publish this 
data through the UCSC EyeBrowse genome browser (http://eyebrowse.cit.nih.gov/), 
which contains eye specific tracks. This includes cataracts, glaucoma, myopia, cornea, 
and retina disease candidate gene loci, expressed sequence tag (EST) data from a variety 
of tissues, and serial analysis of gene expression (SAGE) data from two tissues, retina 
and trabecular meshwork. Including our RNA-seq data in this browser allows other 
researchers to benefit because it is a unique dataset that is unlike those currently 
available.  
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5.2 Challenges and special considerations in POAG genetic 
studies 
5.2.1 The importance of consistent clinical definitions: a challenge 
facing consortia 
For a genomic-based study to be successful, there are many costly and time 
consuming steps that must be performed. This includes ascertainment of patient 
samples (this step alone can take years), collection of clinical data, integration of 
databasing systems and their management, large scale DNA extractions, DNA quality 
control checking , and organization of sample manifests. In addition, a large number of 
samples are required to ensure adequate study power, often leading to cross 
institutional collaborations. In the field of human genetics, consortia-based studies (large 
scale collaborations that share resources for the purpose of completing a common goal) 
are an entity that is here to stay. It is often too challenging for one investigator or one 
institution to gather all of the resources needed for a large genomic project, and the 
synergy provided from pooling resources has been effective in the field of human 
genetics.  
However, consortia-based studies are accompanied by their own set of unique 
challenges including, but not limited to, variations in clinical definitions. Depending on 
the disease being studied, this could even include differences in case-control 
phenotyping, where one institution uses a different disease definition than another. 
There can also be cross-institutional differences in clinical data collection methods, the 
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type of clinical data available, their means of measurement, and the time period of 
measure. Consider POAG and intraocular pressure, the most common risk factor. This 
clinical variable is almost always available because it is measured during routine ocular 
examinations. Despite its availability, combining intraocular pressure data in large 
consortia can be challenging due to the following: 1) an institution may have repeat 
measurements for an individual and may have different measurement selection criteria; 
2) there are numerous methods for measuring intraocular pressure, which can increase 
variability when pooling data; 3) measurements may be confounded because POAG 
patients take intraocular pressure reducing medication; and others. There may also be 
issues of missing clinical data, which can vary from site to site, making it impossible to 
adjust for essential covariates or to assess the effect of these traits on the disease of 
interest. Inconsistency in clinical data can make downstream analyses more challenging 
and can introduce error. Clinical variables should be assessed during model building to 
ensure the most accurate conclusions are being drawn. The accurate assessment of 
clinical traits in large genomic studies is essential because POAG, like other complex 
human diseases, is likely caused by a combination of environmental and genetic factors.  
Due to the cost and the enormous amount of work required to perform a well 
powered genome-wide study, many consortia are driven to utilize the generated data in 
secondary analyses. There are many instances of this throughout the literature 
(Monsees, Tamimi et al. 2009). An example study is discussed in Chapter 2 where the 
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NEIGHBOR and GLAUGEN consortia data, collected initially for POAG analysis, was 
used to study the genetics of central corneal thickness. The motivation behind these 
secondary analyses is not only financial; many times the secondary trait is of particular 
interest to the original trait, as it is in the POAG and central corneal thickness study. 
While the motivation behind these secondary analyses is warranted, they present certain 
challenges that should be considered a priori. Like the primary analysis, they may suffer 
from differences in clinical definitions and data availability across sites, which can be 
exacerbated by the fact that the dataset may not have been collected with the secondary 
trait in mind. Again, this can make evaluating the effect of clinical traits difficult. As an 
example based on the analysis presented in Chapter 2, the effect of glaucoma surgery on 
central corneal thickness was evaluated to check for potential confounding within the 
dataset. Importantly, there was no significant difference observed. However, the 
glaucoma surgery data was only available for 38% of the dataset. Complete and 
systematically collected data would be ideal and would further our confidence in our 
analysis of the effect of glaucoma surgery on corneal thickness. 
While these challenges can be overcome, these simple examples highlight the 
need for standard operation procedures, meticulous planning, and forethought. These 
issues, and others, can be avoided by using a prospective study design. In this approach, 
a researcher determines the clinical traits of interest, these are measured at baseline, and 
then participants are followed for years to determine if the disease develops. The Ocular 
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Hypertension Treatment study is an example of a prospective study, and this study 
successfully identified most of the commonly accepted POAG risk factors known to date 
(Gordon, Beiser et al. 2002). This type of approach in combination with genetic data 
would be immensely informative. It would help clarify the effects of clinical variables 
that have been inconsistently associated with POAG because a prospective study design 
allows for an increased confidence of inferences made on causation (Coleman and 
Miglior 2008). However, this is generally unrealistic as prospective studies tend to be 
timely, costly, and do not take advantage of preexisting data. When consortia are formed 
using a traditional case-control study design, like the NEIGHBOR study, data 
consistency issues can be circumvented by careful planning. A thorough review of the 
literature should be performed in order to identify newly discovered clinical risk factors 
that may become of interest. Ideally, as researchers begin to pool data a definitive list of 
clinical variables and their definitions would be predefined and each institution would 
simply extract this data from an in-house database. This can be complicated if an 
institution does not have a well maintained databasing system or if the desired clinical 
variables were not originally collected, leading to post hoc patient chart reviews. This is 
often unavoidable and the cost of such a venture is frequently underestimated. 
Therefore, proper budgeting when a large scale consortia-based project is initiated is 
essential. Recommendations for improving data consistency in a consortia environment 
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include 1) using a prospective study design whenever possible; 2) preplanning of 
designed clinical traits and their definition; and 3) proper budgeting. 
5.2.2 Challenges and methods for dealing with heterogeneity in POAG 
POAG is genetically and clinically heterogeneous (Allingham, Liu et al. 2009; 
Janssen, Gorgels et al. 2013). The most obvious example of clinical heterogeneity in 
POAG is observed by the presence and absence of elevated intraocular pressure. Despite 
elevated intraocular pressure being a major POAG risk factor, an estimated 30-40% of 
POAG cases never display pressures above the normal range, as discussed in Chapter 1 
(Dielemans, Vingerling et al. 1994; Iwase, Suzuki et al. 2004; Varma, Ying-Lai et al. 2004; 
Mudumbai 2013). The presence of clinical heterogeneity may be indicative of genetic 
heterogeneity. Sub-phenotyping can be used for stratified or restricted analyses and, if 
based on biologically meaningful traits, reduces genetic heterogeneity within a sample 
and thereby increases statistical power in a genetic analysis. This is another reason, in 
addition to the concerns described above, that clinical data consistency and accuracy is 
immensely important in POAG genetic studies. In the context of intraocular pressure, 
sub-phenotyping approaches have proven successful. In the NEIGHBOR and 
GLAUGEN POAG meta-analysis, Wiggs et al. identified a region of interest that only 
reached genome-wide significance in a subset of normal tension POAG cases (Wiggs, 
Yaspan et al. 2012). 
 107 
Stratified analysis can be a powerful approach for reducing genetic heterogeneity 
if based on prior biological or statistical evidence (i.e. formal interaction analysis). 
However, researchers should be careful not to randomly stratify a dataset. 
Inappropriately restricted datasets could lead to spurious associations and incorrect 
conclusions (Patsopoulos, Tatsioni et al. 2007). Not properly restricting analysis in the 
presence of clinical heterogeneity can also lead to biases. As described by Burdon et al., 
an example of this was observed in the first POAG genome-wide association study, 
which included a combination of POAG and pseudoexfoliation glaucoma samples 
(Thorleifsson, Magnusson et al. 2007; Burdon 2012). This study identified a significant 
association with variants in the LOXL1 gene and, after performing a stratified analysis, 
determined the signal is restricted to pseudoexfoliation glaucoma cases only 
(Thorleifsson, Magnusson et al. 2007). Without properly reducing the clinical 
heterogeneity within the dataset (subtypes of glaucoma), an incorrect conclusion 
regarding the association of LOXL1 and POAG would have been made. Despite 
removing a large portion (45%) of their cases, the statistical power was increased. 
Researchers must balance the need for increased samples sizes and reducing genetic 
heterogeneity to have the greatest statistical power and detect true genetic association 
signals. 
While the presence or absence of elevated intraocular pressure is the most 
commonly used clinical trait for performing stratified analyses in POAG, other traits 
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should be considered in the future. Although not currently feasible, intracranial pressure 
differences could potentially represent different subtypes of the disease. Due to the 
challenges of measuring intracranial pressure, it is not fully understood how clinically 
variable this trait is in the context of POAG, but it has been suggested that the effect of 
intraocular pressure is directly dependent on the opposing force generated by an 
individual’s intracranial pressure (Fleischman and Allingham 2013; Janssen, Gorgels et 
al. 2013). In addition, there may be other clinical traits that could be used to define more 
homogeneous subsets. As more insight is gained about the biology, genetics, and 
environmental factors involved in POAG etiology, true subtypes of the disease can be 
defined. 
5.3 Future directions summary 
Glaucoma affects a large number of individuals in the United States and is a 
leading cause of blindness world-wide (Tielsch, Sommer et al. 1991; Resnikoff, Pascolini 
et al. 2004; Quigley and Broman 2006). While the work described here directly 
contributes to the field of POAG research, there is still much to be learned about the 
biology, prediction, prevention, and treatment of this disease. Care should be taken 
when collecting related clinical data as better phenotyping is needed for increasing 
statistical power in genetic analyses and our understanding of POAG biology. In future 
POAG research, a high priority should be given to the functional follow-up of 
association signals and to building clinically applicable prediction models.  
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Appendix A 
 
Principal components plot 
Plot of the principal components analysis (PC1 vs PC2) resulting from the combined 
NEIGHBOR/GLAUGEN CCT datasets consisting of 1,117 individuals. Caucasian (CEU), 
Asian (JPT_CHB), and African (YRI) HapMap samples are included as a reference. 
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Appendix B 
 
Quantile-quantile plot 
Q-Q plot of p-values resulting from the CCT genome-wide association study 
conducted using a linear regression model that included sex, age, CCT measurement 
device, and POAG case/control status as covariates. 
 
  
Appendix C 
 
Primers used in Chapters 2 and 3 
Chapter 
Reference 
Amplicon Forward Primer Reverse Primer 
2 CNTNAP4 5’ AGGATACTGCACTGGCAGGT 3’ 5’ TGCTGATAAATGCGAACAGC 3’ 
2 NTM 5’ TGGCTTTGTGAGTGAAGACG 3’ 5’ AGGCCACGCAAGTGTAGTTC 3’ 
2 GAPDH 5’ CGACCACTTTGTCAAGCTCA 3’ 5’ AGGGGTCTACATGGCAACTG 3’ 
3 SIX1 exon1 5’ TTGCAAAGCCTAAGGAGGAG 3’ 5’ AGGACTTGGTGGCTGGTG 3’ 
3 SIX1 exon2 5’ TTTGGGTTGGTGACAGATTG 3’ 5’ GTCCACCATTCCTTTATGCG 3’ 
3 SIX6 exon1 5’ ATAGTCCTGGCGTGCTGATT 3’ 5’ CAGAACGCAGGGCTCTTAAC 3’ 
3 SIX6 exon2 5’ TCCCAAAAGTGCACAACAAA 3’ 5’ TTCCGAAGGAGACTTTGCAG 3’ 
3 SIX6 enhancer1 5’ CGAGTGAACTGTGAAGATCTGTG 3’ 5’ AGGTGAGAACGTTCACAGCCGA 3’ 
3 SIX6 enhancer2 5’ GGGGCTCGAGCGAGTGAACTGTGAAG 3’ 5’ GGGGAAGCTTAGGTGAGAACGTTCAC 3’ 
3 six6a morpholino 5’ CTGGAACATGGAGACTGTAATGTCT 3’  
3 six6b morpholino 5’ AATTGGCAACTGAAACATGAAGGCT 3’  
1
11 
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Appendix D 
 
Coding variants identified by sequencing SIX1 and SIX6 in 518 POAG  
cases and controls 
Gene Coordinates SNP ID Function 
Base 
Change 
AA 
Change 
SIX1 Chr14:61115933  5’ UTR G>T  
SIX1 Chr14:61115932  5’ UTR C>T  
SIX1 Chr14:61115506 rs151189392 Synonymous C>T Lys134Lys 
SIX1 Chr14:61115323 rs200511291 Intronic C>G  
SIX1 Chr14:61115322 rs374507275 Intronic G>C  
SIX1 Chr14:61113320  Intronic delT  
SIX1 Chr14:61113316 rs183396626 Intronic G>A  
SIX1 Chr14:61113278 rs142301715 Missense A>T Asn193Ile 
SIX1 Chr14:61113110 rs368974927 Missense G>T Pro249Leu 
SIX6 Chr14:60976053 rs148591528 5' UTR C>T  
SIX6 Chr14:60976137 rs61746410 Synonymous G>A Leu7Leu 
SIX6 Chr14:60976290 rs45549246 Synonymous C>T Ala58Ala 
SIX6 Chr14:60976393 rs78954112 Missense G>C Glu93Gln 
SIX6 Chr14:60976501 rs146737847 Missense G>A Glu129Lys 
SIX6 Chr14:60976537 rs33912345 Missense A>C Asn141His 
SIX6 Chr14:60977618 rs56098605 Intronic G>A  
SIX6 Chr14:60977756  Intronic C>A  
SIX6 Chr14:60977774  Intronic T>C  
SIX6 Chr14:60977843 rs45549246 Missense T>G Leu205Arg 
SIX6 Chr14:60977864 rs202029915 Missense C>T Thr212Met 
SIX6 Chr14:60977954 rs139302405 Missense G>T Ser242Ile 
SIX6 Chr14:60977955 rs143366401 Synonymous C>T Ser242Ser 
SIX6 Chr14:60978071 rs1061108 3’ UTR G>C  
        Coordinates are based on the Hg19 reference. 
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Appendix E 
 
Most significant SNPs from the imputed chromosome 14 
POAG association analysis 
BP SNP P OR 
Chr14:61091401 rs34935520 3.07E-10 1.27 
Chr14:60976537 rs33912345 4.20E-10 1.27 
Chr14:61095174 rs35155027 4.39E-10 1.27 
Chr14:61072875 rs10483727 5.02E-10 1.26 
Chr14:60811999 rs8015152 8.61E-10 1.27 
Chr14:60847001 rs1254276 1.10E-09 1.26 
Chr14:60957279 rs2093210 1.12E-09 1.26 
Chr14:60813416 rs10151339 1.25E-09 1.27 
Chr14:60886150 rs1272131 1.29E-09 1.26 
Chr14:61008596 rs7159392 2.22E-09 1.25 
Chr14:61013237 rs2351174 2.36E-09 1.25 
Chr14:61021891 rs1955695 2.36E-09 1.25 
Chr14:61025617 rs4442732 2.44E-09 1.25 
Chr14:60848224 rs1313237 4.78E-09 1.25 
Chr14:61006889 rs12883754 7.05E-09 1.26 
Chr14:61007104 rs10146342 7.05E-09 1.26 
Chr14:61012559 rs12589689 7.05E-09 1.26 
Chr14:61005625 rs1010053 8.66E-09 1.25 
Chr14:60789176 rs4901977 9.27E-09 1.25 
Chr14:61025791 rs1555211 9.34E-09 1.25 
Coordinates are based on the Hg19 reference. 
 114 
Appendix F 
Programs used in the ocular transcriptome analysis: 
Fastqc: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
Cutadapt: https://code.google.com/p/cutadapt/ 
TopHat: http://tophat.cbcb.umd.edu/index.shtml 
Samtools: http://samtools.sourceforge.net/ 
Cufflinks: http://cufflinks.cbcb.umd.edu/index.html 
RNAseqViewer: http://bioinfo.au.tsinghua.edu.cn/software/RNAseqViewer/ 
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Appendix G 
 
The number of genes expressed in the trabecular meshwork, cornea, and ciliary body 
ocular tissue samples 
Counts shown are before filtering using two different FPKM thresholds. 
 
 
Sample 
Number of 
expressed genes 
FPKM > 0 
Number of 
expressed genes 
FPKM > 1 
Adult TM 36,685 17,998  
Fetal TM 32,284 16,648  
Adult Cornea 35,494 16,684  
Fetal Cornea 33,611 16,843  
Adult CB 31,544 12,628  
Fetal CB 27,523 13,784  
 116 
Appendix H 
The average distribution of gene biotypes overall in six ocular tissue RNA-seq 
datasets 
Explanation of gene biotype annotation is provided at: 
http://www.gencodegenes.org/gencode_biotypes.html 
Gene  
Biotype 
Average  
Frequency 
Gene  
Biotype 
Average 
Frequency 
3prime_overlapping_ncrna 5.67 polymorphic_pseudogene 7.50 
antisense 546.50 processed_transcript 461.33 
IG_C_gene 9.75 protein_coding 12,361.67 
IG_C_pseudogene 1.75 pseudogene 1,336.17 
IG_J_gene 5.00 rRNA 46.50 
IG_J_pseudogene 1.00 rRNA_pseudogene 47.17 
IG_V_gene 36.67 scRNA_pseudogene 39.67 
IG_V_pseudogene 6.33 sense_intronic 19.17 
lincRNA 273.67 sense_overlapping 28.17 
miRNA 175.83 snoRNA 96.00 
miRNA_pseudogene 1.17 snoRNA_pseudogene 3.00 
misc_RNA 50.83 snRNA 99.50 
Mt_rRNA 2.00 snRNA_pseudogene 1.60 
Mt_tRNA 14.67 TR_C_gene 1.50 
Mt_tRNA_pseudogene 17.33 TR_J_gene 2.20 
ncrna_host 3.83 TR_V_gene 1.50 
non_coding 11.33 TR_V_pseudogene 1.00 
tRNA_pseudogene 4.80 None 514.98 
 
 
 
  
Appendix I 
 
Box plot depicting the distribution of gene expression values in six ocular tissue RNA-seq datasets 
 Gene expression values, measured in FPKM, were log10 transformed. The box shows the 25th, 50th (line), and 75th percentiles. 
Anything greater than 1.5 times the interquartile range is shown as a square above the plot, indicating extreme values. 
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Appendix J 
Top 20 most expressed genes overall from trabecular meshwork, cornea, and ciliary body ocular tissue samples after 
removal of selected gene biotypes 
There is an enrichment of deprecated genes, as annotated by Ensemble (GRCH37). 
Sample Ensemble ID Gene Name LOCUS FPKM 
Adult Cornea ENSG00000251948 AC092279.1 19:24184074-24184165 1,659,680 
Adult TM ENSG00000251948 AC092279.1 19:24184074-24184165 1,514,330 
Adult Cornea ENSG00000252229 AC098691.1 1:91852861-91852949 1,403,690 
Adult TM ENSG00000252229 AC098691.1 1:91852861-91852949 1,277,510 
Adult TM ENSG00000252318 AC097532.1 2:133038646-133038738 337,063 
Adult Cornea ENSG00000252318 AC097532.1 2:133038646-133038738 289,844 
Adult Cornea ENSG00000252197 AC091047.1 8:70602343-70602417 243,812 
Adult TM ENSG00000252197 AC091047.1 8:70602343-70602417 236,462 
Fetal Cornea ENSG00000252229 AC098691.1 1:91852861-91852949 207,419 
Adult Cornea ENSG00000252248 AC093693.1 7:68527370-68527457 168,987 
Fetal Cornea ENSG00000251948 AC092279.1 19:24184074-24184165 161,281 
Adult CB ENSG00000251948 AC092279.1 19:24184074-24184165 161,006 
Adult CB ENSG00000252229 AC098691.1 1:91852861-91852949 153,737 
Adult TM ENSG00000252248 AC093693.1 7:68527370-68527457 79,925 
Fetal TM ENSG00000252229 AC098691.1 1:91852861-91852949 70,744 
Fetal TM ENSG00000251948 AC092279.1 19:24184074-24184165 58,878 
Fetal Cornea ENSG00000252318 AC097532.1 2:133038646-133038738 46,195 
Adult CB ENSG00000228253 MT-ATP8 MT:8365-8572 40,456 
Fetal CB ENSG00000251948 AC092279.1 19:24184074-24184165 38,281 
1
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